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Abstract 
The purpose of the study was to determine the ability of certain fungi to 
biotransform morphine alkaloids into medicinally relevant intermediates. Fungal 
strains screened for their ability to affect biotransformation of morphine alkaloids 
include Cunninghamella echinulata, Helicostylum pirijorme, Pycnoporus sanguinea, 
Pycnoporus cinnabarina, Curvularia lunata and Sporotrichum sulfurescens. The 
research demonstrated that Cunninghamella echinulata N-demethylated thebaine, 
hydrocodone, codeine, oripavine and oxycodone into corresponding nor-compounds in 
varying yields. 
The study further focused on the characterization of the enzyme responsible for 
the biotransformation of thebaine into northebaine by Cunninghamella echinulata. The 
study clearly showed that incubation of the fungal culture with thebaine over a period 
of 48 hours was required to activate the biotransformation process. 
The biotransformation studies with [14C] labeled thebaine showed that N-
demethylation by Cunningham ella echinulata does not involve O-demethylation 
followed by methyl group transfer as suggested in previous studies. 
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1. Introduction 
Opium has been fascinating mankind since the days of recorded history. 
Morphine alkaloids are extensively used as medicines for the treatment of pain and are 
equally abused. The estimated total amount of raw opium produced worldwide in 2007 
was 8200 tons. 1 Raw opium contains varying amounts of morphine (1), codeine (2), 
narcotine, papaverine (3) and thebaine (4).2 The most famous among opiates, morphine, 
was isolated by Friedrich Wilhelm Sertuemer3 in 1805. Even today opium poppy 
remains the only commercially viable source of morphine alkaloids. 
Over the last two decades, a major goal of the Hudlicky group has been to 
develop a practical synthetic route for morphine alkaloids, capable of competing with 
the natural supply. A genuinely practical synthesis would ensure a constant supply of 
morphine (1) to satisfy the world's demand for this valuable drug. Moreover, it would 
eliminate the world's dependency on the production of natural morphine in countries 
where there is political instability such as Afghanistan, the country with the highest 
opium production in the world. 
The Hudlicky group's interest in morphine alkaloids is not limited to their total 
synthesis. In cooperation with Noramco Inc., a subsidiary of Johnson & Johnson, we 
became interested in the conversion of naturally occurring morphine alkaloids into 
more valuable derivatives utilizing economic and environmentally benign 
transformations both chemical and biological. An ideal starting material for the 
preparation of semi-synthetic analgesics is thebaine (4), a minor constituent in the 
latex of opium poppy. Tasmanian Alkaloids, in partnership with Noramco Inc. 
1 
developed a genetically engineered poppy plant, the latex of which contains up to 30% 
thebaine.4 
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Semi-synthetic drugs derived from opiates have affected society for more than 
100 years. The first attempt to make a non-addictive morphine substitute was made by 
the English chemist Charles Robert Albert WrightS. He synthesized the semi-synthetic 
opiate diacetylmorphine (5), better known as heroin, in 1898. Years later, the even 
more addictive properties of heroin (5) compared to morphine were realized and the 
drug had to be taken out of the market in 1910. 
Shortly after the mass production of heroin was stopped, two semi-synthetic 
opioids, oxycodone (6) and hydrocodone (6) were discovered6• Both derivatives are 
still marketed throughout the world as they possess less addictive and euphoric 
properties than morphine. Naltrexone7, (8) an opioid antagonist, is also a semi-
synthetic drug derived from thebaine and is used for the treatment of alcohol and 
opioid dependence. The manufacturing of semi-synthetic opioids represents a 
prospering market. 
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Figure 2. Semi-synthetic opioids 
The current thesis will discuss the production of some of the intermediates for 
the synthesis of semi-synthetic opiates by microbial transformations. N-demethylation 
of morphine alkaloids are the key step in the synthesis of semi-synthetic opioids such 
as naltrexone (8). Chemical dealkylation has the disadvantage of the involvement of 
expensive and sometimes highly toxic reagents8-1O• Microorganisms can be used as an 
alternative means of preparing N-dealkylated drug intermediates. We envisioned 
screening six fungal strains for their ability to N-demethylate six different morphine 
alkaloids. 
Hydroxylation at the C-14 position is an important oxidative procedure in the 
commercial production of morphine-derived antagonists such as naltrexone, naloxone, 
nalbuphine and other medicinally significant compounds. The ability of fungi to 
perform C-14 hydroxylation of morphine alkaloids has been demonstrated in the early 
1960s by Iizuka. l1-13 Out of the six fungal strains tested two transformed thebaine to 
14- hydroxycodeine in varying yields. But the ability of these fungi for C-14 
hydroxylation'had been demonstrated earlierY' 14 
Convinced by the versatility of Cunninghamella echinulata to transform 
morphine alkaloids, attempts to isolate and characterize the enzyme responsible for N-
demethylation were initiated. The vision of Prof. Tomas Hudlicky was to successfully 
3 
isolate the enzyme and clone the appropriate gene for genetic engineering of this step 
in E. coli and enable a commercial production of N-demethylated morphinans by 
fermentation. Apart from the characterization of fungal cultures capable of 
biotransforming morphinan alkaloids, this thesis describes the difficulties in 
developing an enzyme assay to evaluate the activity of demethylase in cell free 
extracts of Cunninghamella echinulata. 
4 
2. Historical 
2.1. Opium poppy and morphine alkaloids 
Papaver somniferum, the opium poppy is one of mankind's oldest medicinal 
plants and it is the only commercial source of the narcotic analgesics morphine and 
codeine. Along with these two morphinans, opium poppy produces approximately 
eighty alkaloids belonging to various classes of tetrahydrobenzylisoquinoline 
alkaloids. IS 
Raw opium is the air-dried milky exudate or latex that is obtained by incising 
the unripe capsules of the opium poppy and has been the traditional source of poppy 
alkaloids. In recent times, the entire plant tops (poppy straw) are harvested, dried and 
then extracted for their alkaloid content in the pharmaceutical industry.16 Extremely 
large profits can be made from smuggling relatively small amounts of opium and 
converting it to heroin. I? The use of bulkier poppy straw in pharmaceutical production 
reduces the chances of using it for illicit opium trade as poppy straw is difficult to 
smuggle, compared to opium. The main producer of medicinal opium is India, whilst 
poppy straw is cultivated in Turkey, Russia and Australia.16 Opium destined for the 
black market originates form the Golden Triangle (Myanmar, Laos and Thailand), the 
Golden Crescent (Iran, Pakistan and Afghanistan) and Mexico.16 Despite millennia of 
compulsive use and abuse the opiates are still unrivalled as analgesics and derivatives 
of opium components continue to be indispensable in modem therapeutics. 
Legal production of opiate raw materials, both latex-derived and poppy straw 
derived, is restricted to assigned countries. The International Narcotics Control Board 
5 
(INCB) is responsible for monitoring the legal supply of, and demand for, opiates in 
addition to maintaining an acceptable global "balance" that accommodates the 
medicinal needs of human populations. The United Nations Office on Drugs and 
Crime (UNODC) compiles annual reports documenting the illicit cultivation of opium 
poppy. 1 
Currently, only India exports raw opium, although other Asian countries China, 
North Korea and Japan are also entitled to its production. Australia, specifically the 
island of Tasmania, supplies a large proportion of the world's thebaine. 16, 4 Thebaine is 
a starting material in the manufacture of several semi-synthetic opiates, including 
oxycodone, oxymorphone, etorphine, and buprenorphine. Additionally, thebaine is the 
starting material for the synthesis of naloxone, naltrexone, nalorphine, and nalbuphine, 
some of which are used to treat opiate poisoning and opium addiction. I? Thebaine was 
mainly obtained as a byproduct from opium. The development of the poppy mutant4 
known as top} (for 'thebaine oripavine poppy 1 '), in 1998, which accumulates 
thebaine and oripavine, facilitated an agriculturally viable supply of thebaine and is a 
crop that carries little risk of diversion for illicit purposes. 
2.1.1. History of morphine alkaloids 
Opium has its origins at the onset of human society and its use almost certainly 
predates recorded history. Opium is undoubtedly the first drug to be discovered by 
mankind 18. Being naturally occurring, it almost certainly predates the discovery of 
alcohol which requires knowledge of the fermentation process required for its 
production. 
6 
The preserved remains of cultivated poppy seeds and pods have been 
discovered in the sites of Neolithic pile-dwelling villages in Switzerland18, 16 of 4th 
millennium Be. It has long been suggested that the knowledge of opium spread from 
Egypt through Asia Minor to the rest of the Old World, but the Swiss discoveries cast 
this theory into doubt. It is possible that the discovery and use of opium originated in 
the eastern reaches of Europe, in the Balkans or around the Black Sea and spread south 
and west from there. 
Around 3400 BC, the opium poppy was being cultivated in the Tigris-
Euphrates river systems of lower Mesopotamia. The Sumerians, the world's first 
civilization and agriculturists, used the ideograms 16, 18, 19 hul and gil for the poppy, 
which means the 'joy plant'. The ancient Sumerians recognized the euphoric properties 
of opium. Their invention of writing spread gradually to other societies and it is from 
them that the Egyptians probably learned about opium. By the end of the second 
millennium BC knowledge of opium was widespread throughout Europe, the Middle 
East and North Africa. References to opium poppy and its preparations appear in the 
Talmud and the Bible. Roman culture incorporated Greek knowledge of opium poppy. 
The routine supplying of opium to Roman soldiers19 and the extensive growth of the 
Roman Empire facilitated the widespread cultivation and supply of the plant for food, 
medicine, and oil. 
The earliest discovery of raw opium itself comes from Egypt where a sample 
was found in the tomb of Cha, dating to the 15th century BC. At around the same time, 
the Egyptian city of Thebes was so famous that Egyptian opium16, 19 was known as 
Thebic opium and the alkaloid, thebaine, obtains its name from the city. In the sixth 
7 
century BC, a Persian text mentioned opium. Opium was called "afiun" by the 
Persians18b.In the third century BC, the Greek philosopher, Theophrastus referred to 
the sap of the pod of poppy plant as "opion" and the poppy juice, "meconion", 
obtained by crushing the entire plant. I8 It has been postulated that the word "opium" 
was derived from the Greek word "opion". 
Crude opium has been used since antiquity as an analgesic, sleep inducer 
(narcotic) and for the treatment of coughs. In the Therapeutic PapyrusI8,20 of Thebes 
(Papyrus of Ebers), dated 1552 BC and in other sources such as the Veterinary and 
Gynecological Papyri from Kahun, dated between 2160 and 1788 BC, opium is 
prominently listed with other natural remedies and drugs. In the Papyrus of Ebers 
opium is included in 700 remedies. I8 Hippocrates (460-357 BC), the father of 
Medicine, suggested drinking hypnotic meconion (white poppy juice) mixed with 
nettle seeds to cure leucorrhea and 'uterine suffocation'. He prescribed preparations of 
opium poppy as a hypnotic, narcotic, stypic and cathartic. He also acknowledged the 
nutritive properties of the seeds. I9 
Opium was used in the early Egyptian, Greek and Arabic cultures primarily for 
its constipating effect in the treatment of diarrhea. Later, opium's sleep inducing 
properties were noted by writers such as Homer, Virgil, and Ovid. I9 In countries where 
alcohol was prohibited because of religious beliefs, opium was commonly used as an 
intoxicant. The socioeconomic importance of opium was described in the travel 
accounts of ancient Portuguese and Dutch mariners who reached the Far East in search 
of opium and spices, especially pepper.21 The nearly bankrupt British East India 
Company stabilized its financial situation with opium exports to China. This made 
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India the main producer of opium. The British forced the Chinese to permit the opium 
trade and consumption that eventually triggered the first (1838-1842) and the second 
(1856-1860) "Opium Wars" between Great Britain and China?l, 22 The Chinese lost 
the war and therefore their efforts to suppress the sale and use of opium failed 
miserably. 
The invention of laudanum, an alcoholic herbal preparation of opium, by the 
Swiss physician Paracelsus established opium as a premium pain killer in Europe. 
Paregoric, or camphorated opium tincture, was used in the treatment of severe diarrhea 
and dysentery. In Dover's powder, powdered opiuml7 was combined with powdered 
ipecacuanha or ipecac to give a popular sedative and diaphoretic to take at the onset of 
colds and influenza. One major drawback of administering crude opium preparation 
was that the content of the active ingredients was unknown to the physician. 
2.1.2. Biosynthesis of morphine alkaloids in opium poppy 
Papaver somniferum is an annual herb with a growth cycle of approximately 
120 days. In general, poppies require fertile, free draining soil which is not overly 
acidic. The best growing climate is temperate, warm with low humidity and not too 
much rainfall during early growthl8. The poppy is a 'long day' photosensitive plant. 
Blossoming requires a growth period of long days and short nights, preferably with 
direct sunlight at least twelve hours daily. 
Agents such as nitrofene and chlortoluron are frequently used to control weeds, 
while treatments with aminophos-methyl, furathiocarb, dimethoate, diazinon or 
malathion can provide protection against insects during stem emergence periods. Seed-
treatment prior to sowing, application of sulfur-. or copper-containing preparations, and 
9 
optimal harvesting times can protect opium poppy from harmful fungi. Virus infected 
plants are usually burnt to restrict the spread of the infection. I6 
Under ideal conditions, the main blossom appears around the ninetieth day 
from germination. The plant produces large solitary flowers, of white, pink, crimson or 
weakly purple color. Maturation of the seed pod/capsule/bulb/poppy head occurs about 
110-150 days after sowing. One pod may produce over 1000 seeds. IS 
Opium is only produced during a ten to twelve day period when the pod is 
ripening. Once it has reached its maturity, the alkaloids are no longer made and are 
broken down in time. Opium is harvested by tapping individual pods. The ripening 
capsules, which are just changing color from blue-green to yellow, are carefully 
incised with a knife to open the latex tubes.17 The initially white, milky latex quickly 
oozes out, but rapidly turns brown by oxidation and coagulates. This raw opium is then 
removed early the following morning (farmers hope that more opium oozes out in 
overnight time from lanced capsule), being scrapped off and molded into balls or 
blocks. Typically these are wrapped in poppy leaves and shade dried because raw 
opium contains a high percentage of water?3 Fresh opium is pale to dark brown and 
plastic. A pod will continue to secrete opium for some days (may be tapped -6 times). 
The average opium yield is 80 milligrams per pod (a hectare of poppies providing 
between 8 and 15 kilograms of raw opium). 
In 1805, a German pharmacist, Friedrich Wilhelm Serturner, isolated 
morphine3 (Morpheus, the Greek God of Dreams)' in its pure form from raw opium. 
Serturner identified morphine as a potent active component of opium. Besides 
morphine (1), which accounts for 10-16% of weight, raw opium contains varying 
10 
amounts of codeine (2) 1-3%, narcotine (10) 1-7%, papaverine (3) 0.8-1 %, thebaine (4) 
0.5-2% and traces of oripavine (9). 
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Figure 3. Naturally occurring morphine alkaloids 
Pathways for morphine biosynthesis 
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The enzymatic synthesis of morphine has been almost completely elucidated; 
many of the encoding genes have been cloned, and the corresponding recombinant 
enzymes have been characterized. Benzylisoquinoline alkaloid (BIA) biosynthesis 
begins with the conversion of tyrosine to both dopamine and 4-
hydroxyphenylacetaldehyde (4-HPAA) (13). Tyrosine decarboxylase (TYDC) 
converts tyrosine to tyramine and dopa (11) to dopamine (12) (Figure 4). Dopamine 
and 4- HPAA are condensed by norcoclaurie sythease (NCS) to yield (S)-
norcoclaurine (14), the central precursor to all benzylisoquinoline alkaloids in plants.24 
(S)-norcoclaurine is converted to (S)-reticuline (18) in a four step enzymatic reaction 
involving three methyl transferases and a P450 hydroxylase25, 26 (CYP80B1) (Figure 4). 
11 
(S)-reticuline is a key branch point intermediate in benzylisoquinoline alkaloid 
biosynthesis and a variety of subsequent enzymatic reactions determine the structural 
type of alkaloid produced. 16 
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Conversion of (S)-reticuline (18) to its (R)-epimer (20) is the first committed 
step in morphine alkaloid biosynthesis. The oxidation and subsequent reduction of (S)-
reticuline (18) to (R)-reticuline (20), via 1,2-dehydroreticuline (19), is catalyzed by 
two enzymes 1,2-dehydroreticuline synthase (DRS) and 1,2-dehydroreticuline 
reductase27 (DRR). Intra-molecular carbon-carbon phenol coupling of (R)-reticuline by 
the P450-dependent enzyme salutaridine synthase (STS) results in the formation of 
salutaridine (21).28 The cytosolic enzyme, salutaridine NADPH 7-oxidoreductase 
(SOR) reduces salutaridine (21) to (7S)-salutaridinol (22).29 Acetyl coenzyme 
A:salutaridinol-7 -O-acetyltransferase (SAT) catalyzes the conversion of salutaridinol 
(22) to salutaridinol-7-0-acetate (23), which spontaneously produces thebaine (4)?O 
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The pathway from thebaine (4) to morphine (1) involves two demethylation steps and 
proceeds by two alternative routes. The demethylation of thebaine results in the 
formation of either neopinone (24) or oripavine (9) depending on the position (6 or 3) 
of demethylation. Neopinone (24) spontaneously forms codeinone (25), which is 
reduced by the NADPH-dependent enzyme codeinone reductase (COR) to form 
codeine (2).31 Demethylation of codeine (2) yields morphine (1). An alternative route32 
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for morphine biosynthesis involves the production of morphinone (26) from oripavine 
(9) by demethylation, followed by COR-catalyzed reduction of morphinone (26) 
yielding morphine (1). This alternative biosynthetic pathway was further proven by the 
preparation of a poppy mutant known as top} (for 'thebaine oripavine poppy 1,).4 The 
seeds of Papaver somniferum (commercial poppy cultivar) were treated with a 
mutagen and the progeny plants were screened for mutants. The mutant top} was 
found to accumulate thebaine (4) and oripavine (9) but not morphine (1) or codeine (2). 
Feeding experiments with radioactive intermediates confirmed that there was a block 
in both arms of the bifurcated pathway at thebaine (4) and oripavine (9). The authors 
postulated a defect in the enzyme thebaine demethylase, which is responsible for the 6-
O-demethylation of both thebaine (4) and oripavine (9). The development of the top} 
mutant not only contributed to the understanding of the biosynthetic pathway of 
morphine alkaloids, but also provided an agriculturally viable supply of thebaine (4) 
and oripavine (9), which are employed in the manufacturing of the vast majority of 
semi-synthetic opioids. The crop of top} mutant carried little risk of diversion for 
illicit purposes due to the absence of morphine. 
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Recently, the cell type-specific localization of benzylisoquinoline alkaloid 
(BIA) biosynthesis was determined.33 Overall the P!ocess from gene expression 
through alkaloid accumulation requires three specialized cell types, companion cells, 
vascular phloem sieve elements and laticifers. Laticifers, the specialized cells in the 
phloem that contain the latex, serve as the site for alkaloid accumulation, not 
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biosynthesis, in opium poppy. Further sub-cellular compartmentalization of BIA 
enzymes occurs due to the cytotoxicitl4 of the pathway intermediates and products. 
The non-cytosolic enzymes in morphinan biosynthetic pathways are localized to the 
endoplasmic reticulum (ER) or ER-derived endomembranes.24 
2.1.3. Pharmacology of morphine analgesics 
The pharmacological attributes of opium poppy (Papaver somniferum L.) have 
been appreciated even before the dawn of civilization. Even today, opium poppy 
remains the only source for the analgesic morphine, the antitussive codeine and the 
muscle relaxants papaverine and noscapine. Thebaine, another natural product of 
opium poppy is used as a starting material for the production of oxycodone and other 
semi-synthetic opiates. 
Morphine is the major pain relieving agent obtained from opium. Unfortunately, 
morphine has the same potential for abuse as opium. Attempts to develop safer and 
more efficient drugs providing analgesia with reduced side effects and abuse potential 
led to the synthesis of heroin (diacetylmorphine) in 1874. Ironically, heroin is more 
addictive than morphine. The first pure opioid antagonist naloxone was produced in 
the 1940s.22 
Opioid receptors 
The important pharmacological differences shown by opioid analgesics are 
derived from their complex interactions with three opioid receptor types, J..L; 8 and K. 
Based on the activities of stereo isomers, the concept of pharmacologically relevant 
receptors for opioids was first elaborated by British medicinal chemists Arnold Beckett 
and Casy in 1954.35 Later, the concept of different modes of interaction of morphine 
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and other analgesics with opioid receptors was suggested by Portoghese in 1965.36 In 
1971, Goldstein proposed that radio labeled compounds might be used to demonstrate 
the existence of these receptors and to characterize them.37 In 1973, when radioligands 
with high specific activities were available, three different groups,38 independently but 
simultaneously, showed that there are stereo-specific opioid binding sites in 
mammalian brain. 
By the mid 1960s, it was becoming clear that the actions of opioid agonists, 
antagonists, and mixed agonist/antagonist could be explained best by their variable 
interactions with multiple opioid receptors36 (portughese 1965). In 1976, the group of 
Martin39 provided the first convincing evidence for this concept. The authors proposed 
three types of opioid receptors, named after the drugs used in these studies viz. mu (p" 
for morphine, which induces analgesia, miosis, bradycardia, hypothermia and 
indifference to environmental stimUli), kappa (K, for ketocyclazocine, which induces 
miosis, general sedation and depression of flexor reflexes) and sigma (fT, for SKF 
10,047 or N-allylnormetazocine, which induces mydriasis, increased respiration, 
tachycardia and delirium). 
The most important neurotransmitter system involved in nociception is 
composed of the endogenous opioid peptides (endomorphins, enkephalins, dynorphins 
and endorphins) and their corresponding receptors (ft, K, c5) which are expressed within 
specialized neurons. In 1975, Kosterlitz40 and coworkers discovered enkephalins. This 
event led to the suspicion that morphine mimicked endogenous analgesic compounds 
and it was not a natural opioid receptor ligand. Further studies proved that the opioid 
receptors are part of the endogenous opioid system. 
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The knowledge that opioid receptors are present in the periphery along with the 
Central Nervous System (CNS) led to the development of functional models of opioid 
action. Preparations of the isolated ileum of the guinea pig and of the vas deferens 
from mouse, rat, rabbit and hamster have been used in pharmacological assays to 
assess the agonist/antagonist properties of opioids. Based on their observations of the 
action of morphine and naloxone41 on guinea pig ileum and mouse vas deferens 
Kosterlitz proposed a fourth type of opioid receptor named delta (t5, deferens ). A few 
years later, Mannalack42 and co-workers showed that the u receptor is non-opioid in 
nature. Thus, there are three main types43, 44 of pharmacologically defined opioid 
receptors, p, K and t5. All the receptors have been cloned confirming their existence 
and all have binding and functional properties consistent with their identities.45, 46 Pain 
relief effects are mediated by all three receptors but to different degrees. 
Studies conducted on the cloned p, K and t5 opioid receptors demonstrate that 
the amino acid sequences of the three receptors are 65% homologous and all of them 
interact with heterotrimeric G-proteins47• The G-protein coupled receptor superfamily 
includes numerous neurotransmitter and hormonal receptors that transmit signals via 
second messengers (cyclic Adenosine monophosphate) or ion channels (K+). 
Alterations in the levels of cyclic AMP during long-term morphine treatments are 
associated with a number of cellular changes, including the development of tolerance 
and physical dependence. 
", receptors are located at the supraspinal sites of the body which includes 
medial thalamus and brain stem. Activation of ", receptors in these areas lead to 
analgesic, respiratory depressant, miotic (pinpoint pupils), euphoric and physical 
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dependence properties of morphine and its related drugs. K receptors are located 
principally within the dorsal horn of the spinal cord. K receptors produce analgesia by 
depressing the initial relay site of pain transmission. K specific drugs produce miosis 
and sedation but not euphoria, physical dependence, or respiratory depression. These 
drugs are known to produce aversive effects in animals and dysphoria in humans. 
Delta receptors are poorly delineated. The activity of each drug at each type of 
receptor indicates whether it activates (agonistic action) or inhibits (antagonistic action) 
the receptor function. 19 
Classification of opioid analgesics by analgesic properties 
Opioid analgesics can be classified using the knowledge of opioid receptors. 
According to its function of activation or inhibition of each type of receptor, each drug 
can be categorized as a pure agonist, a pure antagonist or a mixed agonist/antagonist. 
Agonist 
Substances which bind to a receptor and induce changes in the cell 
characteristic of the natural ligand for the receptor are called agonists. Pure agonists 
exhibit a high binding affinity for (and exert high activity with) fl receptors and they 
also have affinity for kappa receptors. Morphine, the prototype of a pure opioid agonist, 
stimulates opioid receptor of the mu type. As a result, analgesia, relaxed euphoria, 
sedation, a sense of tranquility, reduced apprehension and concern, respiratory 
depression, suppression of the cough reflex, and papillary constriction occurs. 
Examples of naturally occurring opioid agonists are morphine and codeine. Semi-
synthetic opiates heroin (diacetylmorphine), meperidine, methadone, oxycodone, 
hydrocodone, oxymorphone, hydromorphone and fentanyl are also agonists. 19, 20 
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Antagonist 
Pure antagonists bind to opioid receptors with varying affinity, but they do not 
exert agonist activity at any receptor. Two clinically available drugs, naloxone (Narc an) 
and naltrexone (Trexan) are pure opioid antagonists19• Both can compete with the mu 
agonist for the receptor, precipitating withdrawal in an opioid dependent person 
reversing any analgesia caused by the agonist. Naloxone is neither analgesic nor 
subject to abuse. Naloxone is used to reverse the respiratory depression that follows 
acute narcotic intoxication (overdoses). Naloxone is not absorbed from intestine and 
its duration of action is only 15 to 30 minutes. Naltrexone is the first orally absorbed 
pure narcotic antagonist. Naltrexone has a long duration of action, necessitating only a 
single daily dose. Naltrexone is used for the treatment of heroin dependency as well as 
alcoholism.19 Currently methylnaltrexone, a derivative of naltrexone is a preferred 
antagonist for treating opioid dependence because of its restricted ability to cross the 
blood brain barrier.48 Methylnaltrexone reverses the undesired side effects of opioids 
(that are mediated by the peripheral opioid receptors) like respiratory depression or 
withdrawal symptoms, without affecting the central opioid receptors.49 
Mixed Agonist! Antagonist 
A mixed agonist/antagonist exhibits modest agonistic activity at some receptors and 
antagonist effect at another. In general, these drugs are weak mu agonists. Their 
analgesic effectiveness results from stimulation of K receptors. Examples of mixed 
agonist/antagonist are pentazocine, butorphanol, nalbuphine, buprenorphine and 
dezocine.50 Being weak agonist or antagonist of the mu opioid receptor, these drugs do 
not have the potential for respiratory depression or physical dependence. 
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2.1.4. Semi-synthetic opiates 
A vast range of semi-synthetic or totally synthetic morphine-like derivatives 
are produced, which are referred to as opioids. Many of these opioids are analgesics 
but less habit forming and some are antagonistic in action. More than 90% of 
morphine is used to produce other derivatives. For example, antitussive codeine and 
pholcodine are derived from morphine. Analgesics with less side effects 
dihydrocodeine and hydromorphone also are produced from morphine. Heroin or 
diamorphine is the first semi-synthetic opioid from morphine which is highly 
addictive, analgesic and hypnotic. N-alkyl derivative of morphine include nalorphine, 
a mixed agonist-antagonist. 17 
In addition to morphine, thebaine is now utilized for the semi-synthesis of 
useful new drugs. Analgesics oxycodone and oxymorphone are derived from thebaine. 
Another analgesic etorphine a derivative of thebaine is too powerful for human use. 
Etorphine is used to sedate large animals like elephants and rhinos. Etorphine is 
approximately 5000- 10000 times more potent than morphine. 17 Buprenorphine and 
nalbuphine are examples of mixed agonist-antagonist produced semi-synthetically 
from thebaine. Buprenorphine is N-alkyl derivative of etorphine while nalbuphine is 
N-alkyl derivative of oxymorphone. Antagonists in use naloxone and naltrexone are 
N-alkyl derivatives of oxymorphone/ oxycodone which are originally derived from 
thebaine. Thebaine may also be transformed into codeine in about 75% yield. 
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2.2. Microbial biotransformations 
Microorganisms had been the friend and foe of human beings since the dawn of 
civilizations. Without even being aware of the existence of microbes man was using 
them in the production of food and beverages. Before 6000 BC the Sumerians and 
Babylonians were practicing the brewing of beer. References to wine making can be 
found in the Book of Genesis and the Egyptians used yeast for the leavening of 
bread.51 ,52 
In the field of industrial microbiology, microorganisms are put to work to make 
a product by a process called fermentation. Typically, for a cell, fermentation is a way 
of getting energy by breaking down complex organic molecules to simpler ones 
without using oxygen. In the pharmaceutical or biotechnology industry, fermentation 
is any large scale cultivation of microbes occurring with or without air. In recent years, 
microbial fermentations have been revolutionized by the application of genetically 
engineered organisms. Currently antibiotics produced by fermentation include 
bacitracin, streptomycin, neomycin, erythromycin, tetracycline, penicillin and 
chloramphenicol. Genetically engineered organisms produce highly valuable hormones 
like human insulin, human growth hormone and bovine growth hormone by 
fermentation. 53 
In the course of time it was discovered that microorganisms can modify certain 
compounds by enzymatic catalysis. Nowadays this process is called biotransformation. 
The essential difference between fermentation and biotransformation is that there are 
several catalytic steps between the substrate and the product in fermentation while 
there is only one or two in biotransformation. Also, the chemical structures of the 
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substrate and product resemble one another in biotransformation, but not necessarily in 
fermentation. An example of biotransformation is vinegar production which dates 
back to around 2000 BC. Vinegar production is perhaps the oldest and best known 
example of microbial oxidation.51 
2.2.1. Fungal biotransformations 
Fungi play important ecological and economic roles. Being saprophytic, they 
continue the cycle of nutrients through ecosystems. Fungi possess a battery of enzymes 
which are very versatile in the degradation of xenobiotics. White rot fungi are 
generally recognized for their ability to oxidize pollutants. Cunninghamella elegans54 
has been used as a microbial model for mammalian xenobiotic metabolism. This 
ability to degrade xenobiotics makes fungi the best choice for testing the 
biotransformation of various toxic chemicals and drugs. In order to obtain derivatives 
which are potentially useful for detailed pharmacological studies fungal 
biotransformations of existing drugs are also carried out. 55- 59. 
Fungal biotransformations may permit stereospecific conversion of readily 
available starting materials to valuable products. Fungal biotransformation products 
can be utilized in the chemoenzymatic synthesis of pharmaceuticals. Biotransformation 
of cycloalkenones by fungi Curvularia lunata60 (NRRL 2380) produces synthetically 
important chirallactones in high yields. Fungi are useful for mild, selective oxidations 
of lupane substrates at positions C-3, C-7, C-15, C-25 and C-30. Endophytic fungi, for 
example, Aspergillus jumigatus61 can perform stereo-selective biotransformation 
(sulfoxidation) of thioridazine, a phenothiaZine neuroleptic drug. (R)-phenylacetyl 
carbinol is the chiral precursor in the manufacture of pharmaceuticals ephedrine and 
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pseudoephedrine. Filamentous fungi Rhizopus javanicui2 can biotransform 
benzaldehyde into (R)-phenylacetyl carbinol. 
A well known example of fungal biotransformation is the detoxification of 
chlorophenols by white rot fungi. Methylation of phenolic hydroxyl groups or 
reductive dehalogenation is the biotransformation approach of cholorophenols by 
Phanerochaete chrysosporium63 • Chlorophenolic hydroxyl group can also be 
glycosylated by fungi Trametes versicolor and Pycnoporus cinnabarinus. 
Some fungi can even biotransform antifungal agents. The triphenylmethane 
dye, malachite green, is a widely used antifungal agent in the fish farming industry. 
Malachite green was enzymatically reduced to leucomalachite green by the 
filamentous fungi Cunningham ella elegani4 (ATCC 36112). Malachite green was 
also converted to N-demethylated and N-oxidized metabolites, including primary and 
secondary aryl amines. 
Apart from biotransformation of pharmaceuticals and pollutants, fungi also 
playa major role in the biotransformation of terpenoids (also known as isoprenoids) in 
fragrance industry. Many flavors and fragrance compounds contributing to a wide 
range of pleasant scents are biosynthetically derived from isoprene units. An example 
of terpenoid biotransformation is the conversion of limonene to carveol and carvone 
by Penicillium digitatum. 65 
2.2.2. Fungal biotransformation of morphine alkaloids 
In the early 1960s, microbial transformations of morphine alkaloids were 
studied extensively. The prime motive behind biotransformation was to produce more 
effective analgesics from naturally available compounds. Japanese research groups 
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fIrst reported the biotransformation of morphine alkaloids by fungi. Iizuka66 and 
coworkers (1960) described the conversion of thebaine to 14-hydroxycodeine and 14-
hydroxycodeinone by the basidiomycete, Trametes sanguinea. Yamada67,68 (1962) 
showed that Trametes sanguinea transformed codeinone to codeine, 14-
hydroxycodeine and 14-hydroxycodeinone. In 1969, the fungus Trametes cinnabarina 
was also found to convert thebaine to 14-hydroxycodeine, 14-hydroxycodeinone and 
14-hydroxycodeinone N-oxide by Groger70. Stabler73 demonstrated the oxidation of 
morphine to 2,2' bimorphine (pseudomorphine) by fungus Cylindrocarpon didymium. 
Other than fungal transformations, several groups have reported bacterial 
transformations of morphine alkaloids. 
2.2.3. N-demethylation of morphine alkaloids 
N-dealkylation of pharmaceutically important molecules is an important step in drug 
synthesis and manufacture. The N-substituent of many drug molecules has 
considerable pharmacological importance. Variations of the N-substitution may cause 
substantial variation in pharmacological activity75,76. The design of new drugs often 
require removal of the N-alkyl function usually methyl from the parent drug followed 
by N-acylation or N-arylation of the nor- intermediate. 
Direct chemical N-dealkylation reactions are difficult and hazardous to achieve. 
Moreover, chemical dealkylation has the disadvantages of variable product yields and 
the involvement of expensive and highly toxic reagents.77- 79 
Microorganisms can be used as an alternative means of preparing N-
dealkylated drug intermediates with the following benefits. Microbial transformation 
may give rise to increased and more consistent yields. Microbial enzymatic reactions 
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are highly specific. Microorganisms may mediate some reactions which are not 
chemically possible. Above all, microbial transformations are usually conducted under 
mild conditions, in aqueous media, with low cost raw materials as growth media.8o 
A number of groups have reported the biotransformation capabilities of genus 
Cunninghamella. As early as 1968, Mitscher reported the N- demethylation of 6, 14-
endo-ethenotetrahydrothebaine by Cunninghamella echinulata (NRRL-A-11498)69. In 
1984, Sewelf1 reported the biotransformation of codeine to nor-codiene by a number 
of species of Cunninghamella namely C. bainieri C43, C. bertholletiae Cl, C. 
blakesleeana CMI 53585, C. echinulata IMI 199884, C. echinulata C7 and C. 
echinulata NRRL 3655, in yields of approximately 10%. Madyastha72 in 1994, found 
that the fungus Mucor piriformis, transformed thebaine to nor-thebaine in -77% yield. 
Mucor piriformis also produced isomeric thebaine N-oxides. Abel demonstrated the 
synthesis of potential buprenorphine intermediates by selective microbial N and 0 
demethylations in 2002.74 Of the eleven species of Cunninghamella employed in this 
synthesis C. echincelata (NRRL 2384) gave 39% yield of the N-demethylated 
compound. 
Figure 7: N-demethylation of 6,14- endo-ethenotetrahydrothebaine 
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Figure 8: N-demethylation of codeine 
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Figure 9: Synthesis of buprenorphine intermediates 
by microbial N-, 0, or N- and O-demethylation 
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3. Discussion 
3.1. Biotransformation of morphine alkaloids 
3.1.1. N-demethylation of morphine alkaloids by Cunninghamella echinulata 
The presented research discusses the potential of the fungi Cunninghamella 
echinulata (ATCC 9244) to N- demethylate a variety of morphine alkaloids. The strain 
Cunninghamella echinulata (ATCC 9244) used in the present study N-demethylated 
thebaine, hydrocodone, codeine, oxycodone and oripavine. The maximum 
accumulation of the demethylated product was seen when thebaine was fed to the 
cultures. There was a significant difference in the conversion rates of morphine 
alkaloids depending on the morphology of the fungi. When Erlenmeyer flasks were 
used for biotransformation, the fungi produced thick mycelium which aggregate 
together to form a single huge biomass. The conversion rate was low with this 
morphology. Therefore, baffled flasks were used for biotransformation in which the 
fungi grew as small pellets. The surface area of fungal mycelium exposed to the 
medium it grew, containing the alkaloid, increased considerably in the case of pellets 
which led to better biotransformation rates. 
Figure 10: Growth of Cunninghamella echinulata in a baffled flask as small pellets 
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The yield of nor-thebaine product from thebaine was 35-50%. Hydrocodone, 
codiene and oripavine were converted to corresponding N-demethylated products nor-
hydrocodone, nor-codeine and nor-oripavine in 10% yields. The yield of nor-
oxycodone from oxycodone was 15%. This is the first account of microbial N-
demethylation of the alkaloids hydrocodone, oxycodone and oripavine. There was no 
biotransformation when either morphine or oxymorphone was used as the substrate. 
The starting material was recovered in both cases. Morphine and oxymorphone lack a 
methoxy group at both C3 and C6 position. This could be the reason for no 
biotransformation. It may be necessary to have a methoxy group at the C3 or C6 
position, which may help the molecule to fit into the active site of the enzyme 
responsible for demethylation. 
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Figure 11: N-demethylation of morphine alkaloids by Cunninghamella echinulata 
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N-demethylation of thebaine by Thamnostylum piriforme 
The versatility of the genus Cunninghamella in N- demethylation of morphine 
alkaloids have been patented by Carnell and coworkers in 200781 • The only fungal 
transformation reported to date involving the N- demethylation of thebaine, was 
demonstrated by Madyastha K.M. in 2000 using Mucor piriformii2. The fungus 
Mucor piriformis was isolated in India and is not available for purchase. 
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Figure 12: N-demethylation of thebaine 
Thamnostylum (Helicostylum) piriforme (ATCC 8992) is known for 14u-
hydroxylations of steroids83• A screening of fungal strains was done for 14-
hydroxylation of morphine alkaloids. Surprisingly, instead of 14- hydroxylation 
Helicostylum N- demethylated thebaine in 39% yield. Other than steroids Helicostylum 
has only been demonstrated to transform strychnine84. Inspired by the yield of N-
demethylation of thebaine, other morphine alkaloids were tested for biotransformation. 
Interestingly, hydrocodone and oxycodone was reduced at the C6 position with 40% 
and 10-15% yield respectively. When codeine, oripavine and morphine were used as 
the substrate there was no biotransformation. 
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Figure 13: C6 reduction of hydrocodone and oxycodone 
3.1.2. C14- hydroxylation of morphine alkaloids 
Researchers envisaged the discovery of a magic drug which would counteract 
the deleterious effects of opium alkaloids on the human body, without loss of analgesic 
properties85. Attempts have been made to find products that are able to antagonize or 
neutralize the addictive properties of morphine alkaloids. Hydroxylation at the C-14 
position is an important oxidative procedure in the commercial production of 
morphine- derived antagonists such as naltrexone, nalbuphine and other medicinally 
significant compounds. 
Microorganism's ability of C14 hydroxylation of morphine alkaloids has been 
demonstrated in the early 1960s by Iizuka and coworkers.66-68 In fact, this group 
reported the first microbial transformation within the class of morphine alkaloids using 
the fungi Trametes sanguinea. C-14 hydroxylation is a crucial step in the synthesis of 
semi-synthetic opiates like oxycodone. World-wide marketed oxycodone has less 
addictive and less euphoric properties than morphine. 
In an attempt to find novel fungal strains capable of C-14 hydroxylation five 
fungal species namely Trametes (Pycnoporus) sanguinea (ATCC 14622), Trametes 
(Pycnoporus) cinnabarina (ATCC 14623), Sporotrichum sulfurescens (Beauveria 
bassiana, ATCC 7159), Helicostylum (Thamnostylum) piriforme (ATCC 8992) and 
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Curvularia lunata (ATCC 12017) were screened for biotransformation of morphine 
alkaloids. 
T. sanguinea and T. cinnabarina could accomplish C-14 hydroxylation of 
thebaine as reported before. But when hydrocodone was fed to these fungal cultures it 
produced C6 reduction. C6 reduction was also observed with T.sanguinea when 
oxycodone was used as the substrate whereas there was no biotransformation when 
T.cinnabarina was fed with oxycodone. There was no biotransformation when 
codein!(, oripavine or morphine was added to both the cultures. 9-40% yield of 14-
hydroxycodiene was detected in the biotransformation of thebaine by T. sanguinea 
whereas only 15% product accumulated when T. cinnabarina was used as the 
biocatalyst. 
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Figure 14: C14-hydroxylation of thebaine 
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Figure 15: C6-reduction of hydro cod one in the ratio 5:4 
33 
Sporotrichum sulfurescens is known for the hydroxylation of monocyclic 
alcohols,86 l-benzoyl-trans-decahydroquinoline87 and N-acyl-I-adamantamines.88 
Based on this data the fungus was assayed for morphine alkaloid biotransformation. 
No product formation was observed in any of the alkaloid tested (thebaine, 
hydrocodone, oxycodone, codeine, oripavine and morphine). However, two 
unidentified metabolites accumulated in the media in all the biotransformation 
experiments. These metabolites were present in the media even in the absence of 
morphine alkaloids ruling out the possibility of stress induced production. 
Microbiological hydroxylation of 12a-deoxytetracyc1ine by Curvularia lunata 
was established in 1959 by Holmlund.89 Curvularia is also widely known for its 11/3-
hydroxylation of steroids.9o Therefore, the fungal cultures were treated with various 
morphine alkaloids. None of the morphinans tested underwent C14 hydroxylation in 
the presence of Curvularia. However, it is worth noting that C6 reduction was carried 
out on both hydrocodone and oxycodone with 40% yield of dihydrocodeine and 63% 
yield of 14-hydroxydihydrocodeine. Oxycodone biotransformation resulted in the 
formation of both isomers of 14-hydroxydihydrocodeine. Future optimization of C6 
reduction by Curvularia may lead to a commercially viable process in producing 
intermediates for the synthesis of semi-synthetic opiates. Curvularia also produced 
two metabolites (Figure 16) in all the biotransformation procedures irrespective of the 
presence or absence of morphine alkaloids. 
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Figure 16: C6 reduction of oxycodone in the ratio 3:1 by Curvularia lunata 
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Figure 17: Metabolites produced by Curvularia lunata 
Overall, morphine was untouched by all the fungal species. Only 
Cunninghamella biotransformed codeine and oripavine, all the other fungal species did 
not use these as substrates. It can be concluded that the methoxy group at C3 position 
plays a significant role in biotransformations. 
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Figure 18: None of the fungal strains tested transformed morphine 
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Table 1: Biotransformation of morphine alkaloids by various fungi 
Substrate Cunninghamella Helicostylum Trametes Trametes Sporotrichum Curvularia 
echinulata piriforme sanguinea cinnabarina sulfurescens lunata 
Thebaine N-demethylation N-demethylation 14-hydroxy- 14-hydroxy- No biotrans- No biotrans-
35-50% yield 40% yield codeine codeine formation formation 
9-40% yield 15% yield 
Hydrocodone N-demethylation C6 reduction C6 reduction C6 reduction No biotrans- C6 reduction 
10% yield 40% yield 12% yield 35% yield formation 40% yield 
Oxycodone N-demethylation C6 reduction C6 reduction No biotrans- No biotrans- C6 reduction 
15% yield 10-15% yield 19% yield formation formation 63% yield 
Codeine N-demethylation No biotrans- No biotrans- No biotrans- No biotrans- No biotrans-
10% yield formation formation formation formation formation 
Oripavine N-demethylation No biotrans- No biotrans- No biotrans- No biotrans- Not 
9-21% yield formation formation formation formation tested 
Morphine No biotrans- No biotrans- No biotrans- Not No biotrans- No biotrans-
formation formation formation tested formation formation 
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3.2. Characterization of the enzyme involved in demethylation of 
morphine alkaloids from Cunningham ella echinulata 
The Hudlicky group widely appreciates the potential of biocatalysis. The 
starting materials for the total synthesis of analgesic morphine, antitussive codeine, 
antiviral balanol and anticancer 7 -deoxypancreastatin, are dihydyroxylated arenes 
produced by fermentation with recombinant E.coli JM109104• Since a highly efficient 
chemical demethylation procedure for morphine alkaloids remains unavailable, this 
has prompted the more detailed characterization of Cunninghamella echinulata 
biotransformation system for N-demethylation of thebaine in order to identify the 
enzyme mechanism involved. This study was conducted in collaboration with 
Professor Vincenzo De Luca, Department of Biology, Brock University and the 
pharmaceutical company Noramco Inc., a subsidiary of Johnson & Johnson. 
3.2.1 Biotransformation of thebaine into northebaine by cultures of 
Cunningham ella echinulata (ATCC 9244) 
Cunninghamella echinulata (ATCC 9244) fungal cells were transferred to 
individual flasks containing fresh medium to grow for 2 days after which Thebaine 
(0.5 mg/ml) was added for biotransformation studies. Individual flasks were harvested 
at two day intervals by separating the media from the fungal biomass by filtration. 
Analysis of the media and the fungal biomass showed that Thebaine as well as 
biotransformation products were mostly found in the medium (-80% of the alkaloids 
were recovered from the medium). Detailed analysis of alkaloid profiles in the media 
showed that while no biotransformation of thebaine takes place in the first 2 (48 h) 
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days of culture, most of the biotransformation of thebaine into northebaine takes place 
48 to 92 h (day 4) after the addition of thebaine (Figure 19). 
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Figure 19: Conversion of thebaine to northebaine by Cunninghamella echinulata over 
a period of fifteen days. 
By day 4 of biotransformation, more than 50 % of the thebaine has been 
depleted with almost 40 % of this alkaloid being converted to northebaine (Figure 19). 
Beyond day 4 of biotransformation, the level of thebaine conversion slowed down 
almost completely and the level of northebaine accumulation leveled off. Between 
days 4 to 15 of biotransformation a new thebaine biotransformation product identified 
as thebaine-N-oxide, which accounted for approximately 20 % of the total thebaine 
derivatives was found in the media between days 10 to 15 of the fermentation (Figure 
19). This experiment was repeated at least 3 times, some slight variations in the results 
obtained, but in all cases the biotransformation pattern over the first six days remained 
very similar. During the 2 to 4 day period of biotransformation, the fungal culture 
converted an average of 2.6 mglhour of thebaine into northebaine. 
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In order to more precisely determine the kinetics of thebaine conversion into 
northebaine, the experiment was repeated and fungal cultures were harvested more 
frequently between days 2 to 5 for analysis of the biotransformation. The results 
clearly indicate that the conversion of thebaine into northebaine required an incubation 
of two days before it was initiated (Figure 20). 
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Figure 20: Biotransformation of thebaine over a period of 5 days. Thebaine was added 
after two days of fungal growth. Total fungal growth period was seven days. 
Since thebaine could activate this biotransformation reaction in 2 day old cultures 
(Figures 19 and 20), it was investigated if older fungal cultures could also respond to 
thebaine treatment in a similar manner. When thebaine was added to 5 day old fungal 
cultures, they responded by progressively converting thebaine into northebaine over 
the next 5 days (Figure 21). Close to 50 % of the thebaine had been converted into 
northebaine after 5 days of biotransformation as found for the same experiment 
performed with 2 day old cultures. While similar results with small variations in the 
kinetics were obtained when the experiment was repeated with 7 and 8 day old cultures 
(data not shown), the yield in older cultures of northebaine production was only 10 %. 
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Figure 21: Biotransformation of thebaine over a period of 5 days. Thebaine was added 
after five days of fungal growth. Total fungal growth period was ten days. 
The data (Figures 19-21) clearly suggested that fungal cultures at different stages of 
the growth cycle will transform thebaine into northebaine and that the component(s) 
required for this biotransformation are not present constitutively within the culture, but 
might be induced over a period of 48 hours by the addition of thebaine. 
3.2.2 Pretreatment of cultures of Cunninghamella echinulata with a low dose of 
thebaine induces the components required for biotransformation of thebaine into 
northebaine. 
Fungal cells were grown in the presence or absence of a low concentration of thebaine 
(0.05 mg/ml) for 9 days after which 0.5 mg/ml of thebaine was added to each culture 
to test the biotransformation efficiency of the culture. Media harvested for 6 
consecutive days was extracted for alkaloids and was analyzed for northebaine 
production (Figure 22). 
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Figure 22: Biotransformation of thebaine by Cunningham ella echinulata cultures. 
Cells pre-induced with low levels of thebaine already produced maximum amounts of 
northebaine within 24 h of concentrated thebaine addition (Figure 22). In contrast little 
or no biotransformation of thebaine occurred in the first 48 h of culture in uninduced 
cells inoculated with thebaine (0.5 mg/ml). The 48 h lag was followed with a 
progressive increase in the rate of conversion that reached similar levels found in pre-
induced cells by day 13 of the biotransformation (Figure 22). However the levels of 
northebaine declined to zero with further growth of both induced and uninduced cells, 
suggesting that the northebaine was being converted to other compounds with 
incubation time. The lag observed in the formation of northebaine in non-induced 
cultures and the rapid induction of thebaine biotransformation ability by pre-
incubating fungal cells with low levels of thebaine (Figure 19) clearly suggests that 
biotransformation capability is induced in this system. The experiments provide strong 
evidence that the search for enzymes involved in this biotransformation should be 
conducted with 2 day old fungal cells that have been treated for at least further 48 h 
with low levels of thebaine (Figures 19-22). 
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3.3 Identification of enzymes involved in the biotransformation of 
thebaine into northebaine in Cunninghamella echinulata cultures. 
3.3.1 Characteristics of enzymes involved in demethylation reactions: 
In general, demethylase enzymes are usually Cytochrome P45071 , 98, flavin or 
2-oxoglutarate105 dependent oxidases. In one rare case, the demethylase was a 
cobalamin dependent methyltransferase which transferred the methyl group from an N-
to a free hydroxyl group on the molecule99. Cytochrome P450 and flavin dependent 
enzymes are membrane associated, while 2-oxoglutarate dependent enzymes are found 
in the soluble fraction of cell free extracts. Cytochrome P450 enzymes require reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) as cofactor, whereas flavin 
dependent enzymes need flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD) as coenzymes. 2-oxoglutarate dependent enzymes require the 
cofactors a-ketoglutarate (2-oxoglutarate), ascorbic acid and iron. If the demethylase is 
a methyl transferase, then it can either be membrane associated or soluble. The 
cofactors necessary for methyl transferases are S-adenosyl methionine (SAM or 
AdoMet) and S-adenosyl Homocysteine (SAH or AdoHys). 
3.3.2 Putative mechanisms for N-demethylation of morphine alkaloids 
N-demethylation of morphine alkaloids can occur directly98 or via the 
formation of an N-oxide intermediate (Figure 23). In addition, Abel99 reported that N-
demethylation of morphinans in the Cunninghamella could involve a cobalamin 
methyl transferase. They used a deuterium labeled thebaine derivative for feeding 
experiments using Cunninghamella echinulata (NRRL 1384) fungal culture. They 
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reported that 0- demethylation occurs first, which is followed by a methyl transfer 
from N- to 0- position (Figure 23). 
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Figure 23: Putative mechanism for N- demethylation of thebaine 
3.3.3 In vitro enzyme assay development for conversion of thebaine into 
northebaine. 
A number of different approaches were attempted to develop an enzyme assay 
for conversion of thebaine into northebaine. Initial studies were conducted with cells 
that had been induced by adding 0.2 mg thebaine/ml to the cell culture as described in 
Materials and Methods. Unfortunately these extracts were contaminated with residual 
thebaine and northebaine that made impossible to differentiate de novo synthesized 
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northebaine from that already present in the extract due to biotransformation. This led 
to replacing the thebaine with the same concentration of oripavine which was able to 
activate the fungal cell demethylation system. Cell free extracts from these induced 
cultures did not interfere with the detection of any northebaine would be produced in 
enzyme assays since TLC or by UPLC-MS (Figure 24) could resolve this product from 
oripavine and nororipavine contaminants which. 
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Figure 24: Separation of morphinan alkaloid standards by TLC and UPLC-MS. 
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3.3.4 Cell free extracts assayed under different conditions do not convert thebaine 
into northebaine. 
3.3.4.1 Extraction of Frozen cells 
Frozen cells were extracted as described in Method 1 (See Materials and Methods). 
This crude extract was assayed (Appendix 1, Table 1) to test for the presence of a 
Cytochrome P450 or 2-0xoglutarate dependent dioxygenase involved in northebaine 
formation. Under these conditions, no reaction products were detected. 
3.3.4.2 Extraction of fresh cells 
Since storage of cells at -80°C could inactivate the components involved in 
conversion of thebaine into northebaine, fungal cells were grown in the presence of 
oripavine to activate the components involved in conversion of thebaine to northebaine. 
Cells were tested for their biotransformation competence by harvesting media and 
analyzing the alkaloid profiles by TLC at different points in the growth cycle. Since 
maximal conversion appeared to occur 3 days after cells were transferred to fresh 
oripavine containing growth medium, cells were harvested for enzyme assays by 
filtration and were extracted according to Method 2 in Materials and Methods. Enzyme 
assays were performed as described in Materials and Methods to test for the presence 
of a cytochrome P450, 2-oxoglutarate dependent and flavin dependent enzymes that 
might be involved in northebaine formation. The enzyme assays from extracts of fresh 
cells were inactive irrespective of the cofactors used in the assay (Appendix 1, Table 
2). 
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The experiment with fresh cells was repeated with the same assays as described 
in Appendix 1, Table 3). Additional assays were conducted in the presence of AdoMet 
and AdoCys to test if the mechanism involving a cobalamin dependent 
methyltransferase98 might be involved in the conversion of thebaine into northebaine. 
As in the previous experiment, none of the assays performed catalyzed this cell free 
conversion (Appendix 1, Table 3). 
3.3.4.3 Extraction of fresh cell and enzyme assay using the protocol of Gibson. 98 
In 1984, Gibson first reported the N-demethylation of codeine98 by cell-free 
extracts of Cunninghamella bainieri. The mechanism suggested involved an N-
demethylation of tertiary amines to form either an intermediate N-oxide or a 
carbinolamine that led to the accumulation of a carbonyl product during the reaction. 
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Figure 25: Mechanisms98 for N- dealkylation of tertiary amines 
Since the carbonyl product could inhibit the enzyme reaction, semicarbazide-HCI was 
added to enzyme assays to trap this inhibitory intermediate. The development of a 
successful assay required an extraction procedure similar to our protocols except that 
cells were ground with a pinch of sea sand using a mortar and pestle and the buffer 
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used for extraction was 100 mM Tris-HCI (pH 7.5) with 14 mM ~-mercaptoethanol. 
This extraction method with Cunninghamella echinulata cells was repeated and 
enzyme assays were repeated in the presence of semicarbazide-HCI at 2 separate 
concentrations (Appendix 1, Table 4). Unfortunately, none of the assays produced any 
reaction products as already discovered in the studies described in Tables 1 to 3. If a 
reaction product was being produced, the methods used for its detection did not appear 
to be sensitive enough to identify it. 
Since the detection limit for northebaine of the TLC assay has been reported to 
be 1000 ngl06, Ultra Performance Liquid Chromatography- Mass Spectrometry 
(UPLC-MS) which can detect as little as 16 ng was used as a more sensitive tool for 
product identification (Figure 24). Another key feature of UPLC- MS was that the 
chromatograph only requires 10 minutes to identify the reaction product by its 
retention time, its absorbance spectrum and its molecular mass, respectively. 
Unfortunately this method did not identify a clear northebaine reaction product in the 
enzyme assays described in Appendix 1, in Tables 1-5. 
In order to develop an even more sensitive assay than those using TLC or UPLC-
MS (Figure 24), the radioactive substrate, 3e4CH3]-thebaine (Specific activity, 2.035 
Gbq/mmol or 55 mCi/mmol) was obtained. 
Figure 26: Structure of 3[ 14CH3]-thebaine used for the present study 
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With this substrate, the sensitivity of the assay could be improved by at least one 
order of magnitude over the UPLC-MS assay. 
3.3.5 Biotransformation of 3e4CH3]-thebaine into 3e4CH3]-northebaine by 
cultures of Cunningham ella echinulata 
Previous enzymatic studies with cell-free extracts of Cunninghamella bainieri 
suggested that N-demethylation of codeine occurs through the membrane-
associated cytochrome-P450-dependent monooxygenase. Although cultures of C. 
echinulata were extracted by means of identical protocols, none of the conditions 
used by Gibson98 produced northebaine as a reaction product when analyzed by 
UPLC or by thin-layer chromatography (TLC) (Figure 24, Appendix Tables 1 to 5). 
In order to develop a radioactive enzyme assay using, 3e4CH3]-thebaine as a substrate, 
this substrate was first tested in biotransformation studies (Figure 26). As described 
previously (Figures 19-22), a lag phase of 2 days was also observed in the 
biotransformation of 3e4CH3]-thebaine into 3e4CH3]-northebaine. This is clearly seen 
in the TLC autoradiogram where 3e4CH3]-northebaine begins to appear by day 3 after 
substrate addition and in the % conversion of 3e4CH3]-thebaine into 3e4CH3]-
northebaine that was observed when each radioactive spot was counted (Figure 27). 
The results show that 3e4CH3]-thebaine was converted with time essentially 
quantitatively to 3e4CH3]-northebaine with similar kinetics to those observed in non-
radioactive biotransformation studies (Figures 19 to 22). An alternative mechanism 
postulated by Abel99 suggested that N-demethylation may proceed by transfer of the N-
methyl group to the phenolic OH group on C-3 by a regiospecific N- to 0 
methyltransferase. In biotransformation studies with 3e4CH3]-thebaine, the 
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mechanism proposed by Abel99 should have involved loss of the label for 
regiospecific N- to O-methyltransferase activity to occur. Since 3e4CH3]-thebaine 
was almost quantitatively recovered during this biotransformation to 3e4CH3]-
northebaine, it seems unlikely that N-demethylation would occur by this mechanism. 
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Figure 27: Conversion of e4CH3] thebaine into 3e4CH3] northebaine by C. echinulata. 
In order to better reproduce the results of Gibson98, a novel highly sensitive 
assay using 3e4CH3]-thebaine was also developed for detection of labeled 
northebaine in cell-free extracts of C. echinulata. While in biotransformation 
studies (Figure 27), cell-free extracts assayed as described by Gibson, were 
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totally ineffective in producing this compound. Nevertheless, the availability of 
3e4CH3]-thebaine will be extremely important to eventually develop an assay for 
this reaction and to verify what type of biochemical reaction is responsible for 
this biotransformation in C. echinulata. 
3.3.6 Cell free extracts assayed under different conditions do not convert 
3e4CH3]-thebaine into 3[14CH3]-northebaine 
The biotransformation studies (Figure 26) showed that C. echinulata efficiently 
converted 3e4CH3]-thebaine into 3e4CH3]-northebaine. In order to better reproduce 
the results of Gibson, a novel highly sensitive assay using 3e4CH3]-thebaine was 
developed for detection of labeled northebaine in cell-free extracts of C. 
echinulata. However, cell-free extracts assayed as described by Gibson, were 
totally ineffective in producing this compound. Nevertheless, the availability of 
3e4CH3]-thebaine will be extremely important to eventually develop an assay for 
this reaction and to verify what type of biochemical reaction is responsible for 
this biotransformation in C. echinulata. 
3.3.6.1 Development of an extraction protocol to remove fungal contaminants 
interfering with TLC separation of radio labeled alkaloid. 
The Rf of standard 3e4CH3]-thebaine was 0.5 as determined by TLC and 
autoradiography (Section 3.3.8.5 in Materials and Methods) (Figure 28A, lane 1 and 
27B, lane 1). Initial enzyme assays (Section 3.3.8.7, Method 2 & 3 in Materials and 
Methods) with cell free extracts involved stopping the reaction with IN HCI to bring 
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the pH down to 2 and by extracting the hydrophobic fungal contaminant in ethyl 
acetate 3 times. Under these conditions the labeled alkaloids were not extracted. After 
removal of each ethyl acetate layer, the aqueous layer was treated with 2M NaOH to 
bring the pH up to 10 and re-extracted with ethyl acetate 3 times. This procedure 
seemed to extract additional compounds of fungal origin that interfered with the TLC 
(Figure 28A lanes 2 to 7) whereas incubation of 3e4CH3]-thebaine in the presence of 
various substrates but without fungal extract produced the expected radioactive spot 
with an identical Rf to that of 3e4CH3]-thebaine (Figure 28A, compare lanes 1 and 8) 
without production of further non-enzymatic reaction products. 
The retardation caused by fungal contaminants was resolved by stopping 
enzyme assays with 2M NaOH and extracting 3 times with ethyl acetate at pH-lO. 
After concentrating organic layer down to 0.5 mL, an equal amount of water was 
added and the sample was acidified to pH-2-3 using IN HCI and extracted three times 
in ethyl acetate. The aqueous layer was basified as described previously, extracted 3 
times in ethyl acetate and dried in vacuo for TLC after dissolving the residue in 10 ~ 
of methanol. Under these conditions, the TLC resolved the expected radioactive spot 
with an identical Rf to that of 3[14CH3]-thebaine, but no clear 3e4CH3]-northebaine 
reaction products with an Rf of 0.25 could be identified under the reaction conditions 
utilized (Figure 28B, lanes 2 to 8). 
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Figure 28: Development of a TLC autoradiography system for separation and 
analysis of 3e4CH3]-thebaine and 3e4CH3]-northebaine. A. Retardation of 
chromatographic behaviour of radioactive alkaloids by a fungal contaminant extracted 
by ethyl acetate treatment. B. Removal of the fungal contaminant with an alternative 
extraction procedure. A, Lane 1 is 3e4CH3]-thebaine standard (0.1 ~Ci); Lane 2 to 6, 
enzyme assays with 3e4CH3]-thebaine, lane 7 is enzyme assay without 3e4CH3]-
thebaine, Lane 8 is assay without cell free extract. B. Lane 1. 3e4CH3]-thebaine and 
3e4CH3]-northebaine obtained from whole cell C. echinulata biotransformation of 
3e4CH3]-thebaine. Lanes 2 to 8 enzyme assays by elimination of one co-factor at a 
time. 
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3.3.7 Various extraction procedures for proteins and co-factor combinations 
tested in the present study 
While none of the assay conditions (Figure 28) produced a reaction product, 
this extraction protocol and TLC method was used extensively, to repeat the assays 
with 3e4CH3]-thebaine that had already been performed with non-radioactive thebaine 
as a substrate. Unfortunately, none of these experiments were successful to identify the 
conditions required for cell free biosynthesis of northebaine from thebaine. 
3.3.8 Materials and Methods for enzyme assays using 3[ 14CH3] thebaine as 
substrate 
3.3.8.1 Organism 
Cunninghamella echinulata (ATCC 9244) was purchased from American Type 
Culture Collection (ATCC) USA. 
3.3.8.2 Test Compounds 
Thebaine was provided by Noramco Inc. USA. The 3e4CH3]-thebaine (Specific 
activity 2.035 Gbqlmmol; 99% purity) was purchased from American Radiolabeled 
Chemicals, USA. The purity of 3e4CH3]-thebaine was checked by co-chromatography 
of the radioactive compound with pure thebaine using TLC in 2 separate solvents 
(Toluene: Ethyl acetate: Diethylamine in the ratio 70: 20: 10 and Dichloromethane: 
MeOH: NH40H in the ratio 92: 8: 1. Autoradiography of these TLCs revealed that the 
sample contained a single radioactive spot corresponding to pure thebaine. 
3.3.8.3 Chemicals and reagents 
Sorensen phosphate buffer was prepared from Analar grade KH2P04 and Na2HP04, 
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which was purchased from Sigma- Aldrich Chemical Co. Oakville, Canada. Triton X-
100, semicarbazide- HCl , NADH, NADPH and FeS04. 7H20 was also obtained from 
Sigma-Aldrich. 
3.3.8.4 Culture media 
Cunninghamella echinulata was maintained on potato dextrose agar slants at 4 0c. 
Biotransformation broth media contained 2% glucose, 5% com steep liquor and 1% 
nutrient broth (OCN broth) at pH-5.0 that was autoc1aved at 121°C for 15 minutes. 1 
mL spore suspension (prepared by adding 5 mL sterile distilled water into one agar 
slant of culture) was used to inoculate a baffled flask containing 200 mL 
biotransformation broth media. The cultures were incubated at 26°C on a rotary shaker 
(160 rev/ min) for 2 days to produce the pelleted growth form (Figure 10). Thebaine 
dissolved in a minimal amount of IN HCl was added (0.2 mg thebaine /mL) to the 
cultures to induce demethylase activity as suggested by previous experiments (Figures 
19-22). Fungal cell cultures cultivated for were -85 hours before harvesting them by 
filtration and washing them 3 times with Sorensen's phosphate buffer (KH2P04 and 
Na2HP04, 0.66 M, pH- 7.0 with 14 roM j3-mercaptoethanol) to give approximately 109 
fungal pellets. These pellets were either used directly to produce cell-free extracts for· 
enzyme assay or they were frozen in liquid nitrogen and stored in a -80°C freezer. 
3.3.8.5 Purity of 3rt4cH3]-thebaine 
The 3e4CH3]-thebaine (Specific activity 2.035 Obq/mmol)was produced by American 
Radiolabeled Chemicals. The purity of 3e4CH3]-thebaine was checked by co-
chromatography of the radioactive compound with pure thebaine using TLC in 2 
separate solvents (Toluene: Ethyl acetate: Diethylamine in the ratio 70: 20: 10 and 
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Dichloromethane: MeOH: NH40H (92:8:1). Autoradiography of these TLCs revealed 
that that the sample contained a single radioactive spot corresponding to pure thebaine. 
3.3.8.6 Time profile of biotransformations with 3[14CH3]-thebaine 
C. echinulata was grown in 25 mL GCN broth for 48 hours at 26°C and 125 
rpm to produce pellet form of fungal cells in baffled flasks (Figure 10). At this point 
the culture was inoculated 0.5 IlCurie 3e4CH3]-thebaine together with 12.5 mg 
unlabelled thebaine. Samples (1 mL) were harvested for analysis every 24 hr for 
biotransformation product formation. Samples were titrated with NaOH to pH-lO, 
extracted for alkaloids into EtOAc and the EtOAc was evaporated to dryness. Samples 
were dissolved in 10 ml methanol and were submitted to TLC. The spots 
corresponding to 3e4CH3]-thebaine (Rf 0.5) and 3e4CH3]-northebaine (Rf 0.25) were 
harvested from the TLC plates and quantified by counting in a liquid scintillation 
counter. 
3.3.8.7 Preparation of cell free extracts 
Method 1 
Cells free extracts for the initial experiments were prepared from fungal pellets stored 
at -80°C. The frozen cells were ground using mortar and pestle in liquid nitrogen and 
the total proteins extracted using 100mM Tris-HCI buffer, pH 7.5 containing 14mM ~­
mercaptoethanol as reducing agent. The extraction was done at 4 0c. The crude extract 
was filtered through a layer of mira cloth and was centrifuged at 500g for 10 minutes 
at 4°C. The supernatant was desalted through PD10 column and the filtrate was used 
for enzyme assays. The incubation of enzyme was done at 37°C with the substrate and 
co-factors for one hour. 
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Method 2 
The fungal pellets from freshly harvested cells were ground at 4°C to a paste (using 
mortar and pestle with a pinch of sand) in 1mM DTT (dithiothreitol), 14 mM ~­
mercaptoethanol, 15% glycerol and 50mM Tris HCI at pH-7.5. The cells were 
sonicated (using a sonicator provided by Fisher Scientific Co. USA) at speed 4 
continuous, for one minute X 4 with intermittent cooling on ice for one minute. After 
sonication, the crude extract was filtered through a layer of mira cloth and was 
centrifuged at 500g for 10 minutes at 4°C. The supernatant was desalted through 
PD10 column and the filtrate was used for enzyme assays. The incubation of enzyme 
was done at 37°C with the substrate and co-factors for one hour. 
Method 3 
The fungal pellets from freshly harvested cells were ground at 4 °C to a paste (using 
mortar and pestle with a pinch of sand) with 10 mL phosphate buffer and the 
homogenate was transferred to a 50 ml centrifuge tube. The cells were sonicated (using 
a sonicator provided by Fisher Scientific Co. USA) at speed 4 continuous, for one 
minute X 4 with intermittent cooling on ice for one minute. The homogenate was 
filtered through a layer of mira cloth and washed with 10 mL phosphate buffer X 2 
into a precooled 125 mL Erlenmeyer flask to which Triton X-100 solution (10% w/v) 
was added to give a surfactant concentration of 0.33% w/v. The mixture was agitated 
on a radial shaker at 4 °C for 30 minutes and the suspension was immediately 
centrifuged at 32,000 g for 20 minutes at 4 °C to remove the cell debris. The 
supernatant was decanted to give the cell free extract which was used for enzyme 
assays. 
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3.3.8.8 Estimation of total proteins in cell free extracts 
Total protein concentration in the cell free extracts was determined by the Bradford's 
method Reagents: Bradford's reagent- 40 ilL, Protein solution- 10 ilL, Millipore water-
150 ilL, Reaction time - 15 to 30 minutes. The reaction was measured using 
spectrophotometer at 595nm. 
3.3.8.9 Estimation of N-demethylase activity 
A typical example of a set of enzyme assays performed in the present study using 
radio-labeled thebaine is given in the table below (Table 2). The concentration of total 
proteins present in the fungal extract was 2mglmL. 
Table 2: Enzyme assays by elimination of one co-factor at a time. 
Sample 1 2 3 4 5 6 7 8 
Protein (2mL) + + + + + + +B + 
14C Thebaine (0.1 IlCi) + + + + + + + -
Thebaine (100 Ilg) + + + + + + + -
NADPH(lmM) + + + + - - + -
NADH(1mM) + + + - + - + -
Ferrous (5mM) + + - + + - + -
Semicarbazide-HCI (15mM) + - + + + - + -
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3.3.8.10 Thin Layer Chromatography (TLC) determination of 3rt4CH3]-
northebaine 
TLC solvent: Toluene: Ethyl acetate: Diethyl amine in the ratio 70: 20: 10. After the 
enzyme assays the reaction was stopped by adding 2N NaOH to get pH-lO. The 
samples were processed by extracting the alkaloids into EtOAc (4 mL X 4) at pH-lO. 
The combined organic layers were dried in vacuo & re-dissolved in ImL EtOAc. 500 
~L milli Q H20 was added to the EtOAc extract, acidified using acetic acid and 
extracted twice. The aqueous layer was basified and extracted again using EtOAc 
(4mL x 3).The last basic organic extracts were dried in vacuo & used for TLC. The 
TLC was exposed to phosphor screen (purchased from Amersham Scientific Co., USA) 
overnight and the images were developed by a Fujifilm image reader. Quantification of 
the 3e4CH3]-northebaine formed if any was done by scraping the corresponding TLC 
spot and subjecting it to scintillation counting using Beckman's Scintillation counter. 
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4. Conclusions and future work 
In the course of the studies, we discovered the capability of Helicostylum 
pirijorme, to transform thebaine to nor-thebaine. We established the versatility of 
Cunninghamella echinulata to perform N-demethylation of a variety of morphine 
alkaloids. Even though the genus Cunninghamella is speculated to biotransform 
morphine alkaloids81 , none of the morphinans other than codeine and a thebaine 
derivative (buprenorphine) had been tested so far (Table 1). Our results indicate that 
Cunninghamella echinulata is truly a microbial model for mammalian drug 
metabolism. It can also be concluded that when there is a ketone at the C-6 position, 
fungal strains tend to reduce the ketone in varying yields depending on the alkaloid 
and the particular fungus being used. The only exception to this occurred with 
Cunninghamella that N-demethylated both hydrocodone and oxycodone which are 
both ketone at the C-6 position. It is worth noting that the morphology of the fungi also 
has an influence on the yield of biotransformation (Table 1). When Cunninghamella 
echinulata grew as single large biomass, the biotransformation yield of nor-thebaine 
was approximately three times lower when compared to that obtained when it grew as 
small pellets (picture: p28). The small pellet morphology increases the surface area of 
contact with the broth containing the substrate for biotransformation. This increases 
the chances of absorption of the substrate and the incorporation of oxygen into cells. It 
is assumed that these factors contribute to the increase in yield. 
A possible industrial application of fungal N-demethylation might involve 
immobilization of the enzyme(s), to allow a continuous yield of the N-demethylated 
product. But this method may require the addition of expensive co-factors to the 
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reaction media. An alternative to this method is to identify the gene and clone it to 
produce a recombinant E.coli expressing this gene. The recombinant E.coli can be 
grown in large fermenters and the bacterial cell will provide the co-factors necessary to 
perform the reaction, thus saving the addition of co-factors to the media. 
It has been demonstrated in the past that both viable and cell-free extracts of 
Cunninghamella bainieri are capable of N-demethylating codeine.71 It has also been 
reported that the N-demethylase is probably membrane bound cytochrome P450 
monooxygenase. However, all our attempts to repeat the N-demethylation of thebaine 
using cell free extracts of Cunninghamella echinulata were unsuccessful. We were 
unable to reproduce the N-demethylation reaction performed by the cell extracts of C. 
bainieri even after having a powerful tool like radioactive substrate, when [14C] 
thebaine was used as substrate. 
Future work in the area of engineering a recombinant E.coli can proceed in two 
ways either using the gene from fungus or using the gene from mammalian cell lines. 
If an enzyme assay could be developed for testing the conversion of thebaine to nor-
thebaine using cell free extracts of Cunninghamella echinulata, then we can 
characterize the enzyme and clone the gene. If it is a soluble enzyme, then isolation of 
the protein will be easier compared to a membrane- bound cytochrome P450 
monoxygenase as reported earlier. If the enzyme is membrane bound, then probably 
isolation of the gene transcripts using degenerate primers of known cytochrome P450 
demethylases will be the focus. Designing the primers, cloning and characterization of 
each of the transcript can be a very time-consuming effort. It is known that human 
liver microsomes are capable of N-demethylating morphine alkaloids. The human 
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cytochrome P450 demethylases can be cloned and tested for N- demethylation of 
morphine alkaloids. This second approach may provide results faster than isolating 
enzyme from the fungus. 
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5. Experimental Section 
5.1 General Experimental Details 
Liquid reagents were distilled prior to use, and commercial solids were used as 
supplied. Analytical thin-layer chromatography was performed on Silicycle 60 A 250 
Jlm TLC plates with F-254 indicator. Flash column chromatography was performed 
using N atland 200-400 mesh silica gel. Melting points were recorded on a Hoover 
Unimelt apparatus and are uncorrected. IR spectra were obtained on a Perkin_Elmer 
One FT-IR spectrometer. IH- and 13C-NMR spectra were recorded on a Bruker (300 
MHz or 600 MHz) spectrometer. All chemical shifts are referenced to TMS or residual 
undeuterated solvent (CHC13, DCM). Separation by HPLC was either performed on a 
Hitachi L-6000 HPLC using a Hitachi L-4000H UV detector (254 nm) with a 
Phenomenex primespher 5 Cl8 HC 250 x 10 mm column; 2 mllmin flow; 5 mM 
KH2P04, 0.1 % NEt3, pH = 2.8 adjusted with 2N HCI : MeOH (80:20) or performed 
on an Agilent 1100 series HPLC using a Phenomenex primesphere 5 C18 HC, 150 x 
4.6 mm column and 1.3 mllmin flow. Compounds were detected at 280 nm and 
opioids were eluted with a gradient of 5 mM KH2P04, 0.1 % NEt3, pH = 2.8 adjusted 
with 2N HCI and MeOH. Mass spectra were recorded on KratoslMsI Concept 1 S mass 
spectrometer at Brock University. 
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5.2 Experimental procedures 
Maintenance of fungi and biotransformation protocols 
5.2.1.0. Cunningham ella echinulata, A TCC 9244 was propagated on potato 
dextrose agar (ATCC medium 336) slants at 26°C. Mature slants (>7 days) were used 
for the preparation of spore suspensions. 
5.2.1.1. FermentationlBiotransformation media 
Batch fermentations were carried out at 26°C with vigorous aeration (150 rpm in 
baffled flasks on an orbital shaker) for up to 15 days. GCN medium (glucose, 2%; 
com steep liquor, 5%; Difco nutrient broth, 1%; pH 5.0) was used to promote high 
levels of N-demethylation.9l 
5.2.1.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in lL 
reaction vessels. All media were seeded with O.5ml concentrated spore suspension 
made up in sterile distilled water (typically 3m1 for 1 slant). Substrate, thebaine, 
hydrocodone, codeine, morphine, oxycodone or oripavine, (100 mg mrl dissolved in 
IN HCI except in the case of codeine. Codeine phosphate, 150mg mCl was dissolved 
in distilled water) was added to the fermentation medium to give a final concentration 
of 0.5mg mrl 24 to 48 hours post-inoculation. Progress of the biotransformation was 
followed by TLC as described below. 
5.2.1.3. TLC and sample preparation 
The progress of the alkaloid demethylation reaction was monitored by TLC in a 
solvent system comprising of DCM: MeOH: NIL!OH (92: 8: 1, v/v/v). Samples for 
analysis were prepared by mini work-up. A mini work-up was performed as follows: 
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2ml of broth was centrifuged, the supernatant was basified using conc.NH40H and 
then extracted with dichloromethane (DCM). 
5.2.1.4. Analysis of products 
After a biotransformation was complete, the broth was separated from fungi by 
centrifugation, followed by filtration. The broth was basified to pH lOusing conc. 
NH40H (except in the case of morphine for which pH was adjusted to 8) and extracted 
with chloroform (3x2S0ml). The combined organic layers were dried over Na2S04 and 
the solvent was evaporated in vacuo. The biotransformation products were separated 
by flash column chromatography on silica gel using the eluents CHCh and MeOH. 
The products were identified by NMR (13C & 1 H), JR, MS and HPLC, and matched to 
literature data when possible. 
5.2.2.0. Trametes sanguinea, ATCC 14622, was propagated on yeast mold agar 
(ATCC medium 200) slants at 26°C. Mature slants (>7 days) were used for the 
preparation of spore suspensions. 
5.2.2.1. Fermentation media 
Batch fermentations were carried out at 30°C with vigorous aeration (160 rpm on an 
orbital shaker) for up to 22 days. M-2 medium92 ( glucose, 1 %; peptone, 0.2%; 
beef/meat extract, 0.1 %; yeast extract, 0.1 %; com steep liquor, 0.3%; pH 5.0)7 was 
used for biotransformation.67-69 
5.2.2.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in 1 L 
reaction vessels. All media were seeded with O.Sml concentrated spore suspension 
made in sterile distilled water (typically 3ml for 1 slant). Substrate (lOOmg mrl 
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dissolved in IN HCI except in the case of codeine. Codeine phosphate, 150mg mr! 
was dissolved in distilled water) was added to the fermentation medium to a final 
concentration of 0.5mg mr!, 4 days post-inoculation. Progress of the biotransformation 
was followed by TLC. 
TLC, sample preparation and analysis of products are same as in the case of 
Cunninghamella echinulata. 
5.2.3.0. Trametes cinnabarina, ATCC 14623, was propagated in yeast mold broth 
(ATCC medium 200) at 26°C. Mature cultures (>7 days growth) were used for the 
inoculation of biotransformation media. The culture was maintained on yeast mold 
agar slants. 
5.2.3.1. Fermentation media 
Batch fermentations were carried out at 30°C with vigorous aeration (160 rpm on an 
orbital shaker) for up to 9 days. NRM or nutrient rich medium (Glucose, 0.5%; 
KH2P04,0.05%; L-asparagine, 0.052%; Yeast Extract, 0.05g; KCI, 0.05g; MgS04 x 
7H20, 0.05%; FeS04, 0.001 % ; dissolved in 950mL distilled water and 50mL mineral 
salt solution was added. pH- 4.5; mineral salt solution- Mn(CH3COO)2 x 4H20, Smg; 
CUS04 x 5H20, 3mg; ZnS04 x 7H20, 2mg; Ca(N03h x 4H20, 50mg; d/w, 50mL) was 
used for biotransformation.7o 
5.2.3.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in 1L 
reaction vessels. All media were seeded with 1mL mature culture. Cultures were static 
during the growth period. Substrate (lOOmg mr! dissolved in IN HCI except in the 
case of codeine. Codeine phosphate, 150mg mr! was dissolved in distilled water) was 
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added to the fermentation medium to a final concentration of O.5mg mrl, '7 days post-
inoculation. Progress of the biotransformation was followed by TLC. TLC, sample 
preparation and analysis of products are same as in the case of Cunninghamella 
echinulata. 
5.2.4.0. Helicostylum piriforme, ATCC 8992 was propagated on cornmeal yeast 
glucose agar ,CMYG (ATCC medium 310) slants at 24°C. Mature slants (>7 days) 
were used for the preparation of spore suspensions. 
5.2.4.1. FermentationlBiotransformation media 
Batch fermentations were carried out at 26°C with vigorous aeration (125 rpm in 
baffled flasks on an orbital shaker) for up to 15 days. Glucose Corn steep liquor Salt, 
GCS medium (Glucose, 3%; Com Steep Liquor, 1 %; K2HP04, 0.2%; KH2P04, 0.1 %; 
NaN03, 0.2%; KCI, 0.05%, MgS04 * 7 H20, 0.05%, FeS04 * 7 H20, 0.002%), was 
used for biotransformation.83 
5.2.4.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in lL 
reaction vessels. All media were seeded with 0.5ml concentrated spore suspension 
made up in sterile distilled water (typically 3ml for 1 slant). Substrate (lOOmg ml-1 
dissolved in IN HCI except in the case of codeine. Codeine phosphate, 150mg ml-1 
was dissolved in distilled water) was added to the fermentation medium to give a final 
concentration of 0.5mg mrl 24hours post-inoculation. Progress of the 
biotransformation was followed by TLC. TLC, sample preparation and analysis of 
products are same as in the case of Cunninghamella echinulata 
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5.2.5.0. Curvularia lunata, ATCC 12017 was propagated on Rabbit food agar 
(ATCC medium 340) slants at 24°C. Mature slants (>14 days) were used for the 
preparation of spore suspensions. 
5.2.5.1. FermentationlBiotransformation media 
Batch fermentations were carried out at 27°C with vigorous aeration (150 rpm in 
baffled flasks on an orbital shaker) for up to 10 days. Beef Extract Medium, BEM 
(Glucose, 0.5%; Peptone, 0.1 %; Yeast Extract, 0.1 %; Beef Extract, 0.1 %) was used for 
biotransformation.93 
5.2.5.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in lL 
reaction vessels. All media were seeded with O.5ml concentrated spore suspension 
made up in sterile distilled water (typically 3ml for 1 slant). Substrate (lOOmg mrl 
dissolved in IN HCI except in the case of codeine. Codeine phosphate, 150mg ml-1 
was dissolved in distilled water) was added to the fermentation medium to give a final 
concentration of 0.5mg mrl 48hours post-inoculation. Progress of the 
biotransformation was followed by TLC. TLC, sample preparation and analysis of 
products are same as in the case of Cunninghamella echinulata 
5.2.6.0 Sporotrichum sulfurescensl Beauveria bassiana, A TCC 7159 was propagated 
on Potato Dextrose Agar, PDA (ATCC medium 336) slants at 24°C. Mature slants 
(>7 days) were used for the preparation of spore suspensions. 
5.2.6.1. FermentationlBiotransformation media 
Batch fermentations were carried out at 28°C with vigorous aeration (150 rpm in 
baffled flasks on an orbital shaker) for up to 7 days. Glucose, Corn steep liquor 
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medium (Glucose, 1 %; Com steep liquor, 2%, and tap water not distilled water) was 
used for biotransformation.86 
5.2.6.2. Biotransformation protocols 
Typically, biotransformations were carried out in 200 ml fermentation media in lL 
reaction vessels. All media were seeded with 0.5ml concentrated spore suspension 
made up in sterile distilled water (typically 3ml for 1 slant). Substrate (lOOmg mrl 
dissolved in IN HCI except in the case of codeine. Codeine phosphate, 150mg mrl 
was dissolved in distilled water) was added to the fermentation medium to give a final 
concentration of 0.5mg ml-1 4 days post-inoculation. Progress of the biotransformation 
was followed by TLC. TLC, sample preparation and analysis of products are same as 
in the case of Cunninghamella echinulata 
5.3. General experimental details for enzyme assays 
5.3.1. Bradford's Assay for determining the concentration of total proteins 
Reagents:Bradford's reagent - 40IlL, Protein solution -1OJ.LL, 
Millipore water -150 ilL, Reaction time - 15 to 30 minutes. 
The reaction was measured using spectrophotometer at 595nm 
5.3.2. Thin layer chromatography (TLC) for enzyme assays 
TLC solvent: Toluene: Ethyl acetate: Diethyl amine in the ratio 70: 20: 10 
Staining was done using Marquis reagent by spray technique 
5.3.3. Marquis reagent: Sulfuric acid - 100mL, Formaldehyde - 3mL 
Rr values: Thebaine - 0.58, Northebaine - 0.26, Oripavine - 0.30, 
Nororipavine - 0.18. 
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5. 4. Biotransformation product identification 
Me°rA Ih-
o :-OX?NH 
Norhydrocodone (34). 
The title compound 34 was isolated following the protocol for biotransformations 
using Cunningham ella echinulata, ATCC 9244 in 10% yield as colorless solid. Data 
for 34 are identical to those published in the literature.94 mp 149 - 151°C 
(MeOHldiethyl ether); Rf 0.25 (DCM : MeOH : NH40H, 98:2:1); [a] D20 = -83.988° 
(c = 0.215, CHCh), [a] D20 = -54.823° (c = 0.58, MeOH); literature value is [a] D11 = 
-4.0° (c = 1.0, MeOH)IOO; IR (film) Vrnax: 3369, 2928, 1725, 1636, 1609, 1504, 1439, 
1274, 1061 cm-I; IH NMR (CDCh, 600 MHz) 8: 6.74 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 
8.2 Hz, 1H), 4.66 (s, 1H), 3.93 (s, 3H), 3.48 - 3.52 (m, 1H), 2.85 - 2.95 (m, 2H), 2.79 
(d, J = 18.5 Hz, 1H), 2.71 - 2.77 (m, 1H), 2.55 (dt, J = 12.6, 3.2 Hz, 1H), 2.45 (dt, J = 
13.8,4.6 Hz, 1H), 2.40 (td, J = 13.8,4.6 Hz, 1H), 1.97 (td, J = 12.3,4.8 Hz, 1H), 1.82 
- 1.91 (m, 2H), 1.22 (qd, J = 13.3, 3.2 Hz, 1H); ppm; 13C NMR (CDCh, 150 MHz) 8: 
207.6, 145.5, 142.9, 127.3, 126.3, 119.9, 114.7,91.6,56.8,52.4,47.7,43.0,40.3,39.0, 
36.0,30.8,25.8 ppm; MS (En mlz (%) 285 (9), 87 (11), 86 (21), 85 (65), 84 (35), 83 
(100), 49 (14), 48 (13), 47 (33); HRMS (En calcd for C17HI9N03: 285.1365, found 
285.1364. 
Norcodeine (33). 
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The title compound 33 was isolated following the protocol for biotransformations 
using Cunninghamella echinulata, ATCC 9244 in 10% yield as colorless solid. Data 
for 33 are identical to those published in the literature.95 mp 182 - 183°C 
(MeOH/diethyl ether); Rf 0.22 (DCM : MeOH : NH40H, 98:2:1); [a]D20 = -90.971° (c 
= 0.224, CHCh); literature value is [a]D28 = +115.23° (c = 1.09, 
CHCh)lOI(enantiomer); IR (film) Vrnax: 3309, 3000, 2935, 2837, 1635, 1603, 1504, 
1453, 1282, 1127, 943 em-I; IH NMR (CDCh, 600 MHz) 5: 6.70 (d, J = 8.2 Hz, 1H), 
6.60 (d, J = 8.2 Hz, 1H), 5.72 - 5.76 (m, 1H), 5.28 (dt, J = 9.9, 2.5 Hz, 1H), 4.89 (d, J 
= 6.4 Hz, 1H), 4.17 - 4.22 (m, 1H), 3.87 (s, 3H), 3.65 - 3.69 (m, 2H), 2.98 (td, J = 12.1, 
4.4 Hz, 1H), 2.86 - 2.93 (m, 2H), 2.83 (d, J = 18.7 Hz, 1H), 2.59 - 2.63 (m, 1H), 1.88 -
1.98 (m, 2H) ppm; 13C NMR (CDCh, 150 MHz) 5: 146.4, 142.2, 133.7, 131.1, 128.2, 
127.4, 119.6, 112.8, 91.9, 66.3, 56.3, 52.0,43.9,41.3, 38.5, 36.6, 31.4 ppm; MS (EI) 
mlz (%) 285 (39), 87 (13), 86 (17), 85 (70), 84 (25), 83 (100), 82 (10), 59 (34), 49 (11), 
47 (25),45 (13), 44 (29), 43 (19),42 (12); HRMS (EI) calcd for C17HI9N03: 285.1365, 
found 285.1368. 
MeoA 10 
o ;: ~-'~NH 
MeoA) 
Northebaine (37). 
The title compound 37 was isolated following the protocol for biotransformations 
using Cunninghamella echinulata, ATCC 9244 and Helicostylum pirijorme, ATCC 
8992, in 35-50% and 39% yield respectively, as colorless solid. Data for 37 are 
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identical to those published in the literature.95 mp 109 -111°C (MeOHldiethyl ether); 
Rf O.59 (DCM: MeOH: N~OH, 98:2:1); [a]D20 = -197.956° (c = 0.31,5% MeOH in 
CHCb); literarture value is [a]D23 = -200° (c = 0.1,5% MeOH in CHCb)82; IR (film) 
Vrnax: 3295, 3004, 2931, 2837, 1668, 1607, 1505, 1447, 1234, 1019 em-I; IH NMR 
(MeOH-d4, 600 MHz) 5: 6.74 (d, J = 8.2 Hz, 1H), 6.64 (d, J = 8.2 Hz, 1H), 5.63 (d, J = 
6.5 Hz, 1H), 5.27 (s, 1H), 5.15 (d, J = 6.5 Hz, 1H), 4.00 (d, J = 6.4 Hz, 1H), 3.84 (s, 
3H), 3.62 (s, 3H), 3.07 - 3.19 (m, 3H), 2.94 (dd, J = 13.4,4.5 Hz , 1H), 2.14 (dt, J = 
12.9,5.0 Hz, 1H), 1.79 (dd, J = 13.2,2.8 Hz 1H) ppm; 13C NMR (MeOH-d4 150 MHz) 
5: 152.9, 144.8, 142.8, 133.2, 131.6, 127.4, 119.2, 113.7, 111.7,95.5,88.7,55.8,54.0, 
53.4,46.1,38.4,37.5,36.2, ppm; MS (EI) mlz (%) 298 (3), 297 (13), 88 (19), 86 (65), 
84 (100), 49 (16),47 (21),45 (40); HRMS (EI) calcd for CI8HI9N03: 297.1365, found 
297.1368. 
HOM 1.0-
° :: \r?NH 
MeoA) 
Nororipavine (36). 
The title compound 36 was isolated following the protocol for biotransformations 
using Cunningham ella echinulata, ATCC 9244 in 9-21 % yield as colorless oil. Data 
for 36 are identical to those published in the literature.95 Rf 0.15 (DCM : MeOH : 
NH40H, 98:2:1); [a]D20 = -69.39° (c = 0.475, MeOH); literature value is [a]D = 90° (c 
= 0.27, MeOH)103; 1H NMR (MeOH-~, 600 MHz) 5: 6.66 (d, J = 8.2 Hz, 1H), 6.63 (d, 
J = 8.2 Hz, 1H), 5.94 (d, J = 6.4 Hz, 1H), 5.39 (s, 1H), 5.23 (d, J = 6.4 Hz, 1H), 4.57 
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(d, J = 6.8 Hz, IH), 3.67 (s, 3H), 3.21 -3.38 (m, 6H), 2.25 - 2.36 (m, IH), 2.02 (d, J = 
13.5 Hz , IH) ppm; 13C NMR (CDCb, MeOH-d4 150 MHz) D: 154.5, 143.6, 140.1, 
131.7, 124.7, 122.9, 119.7, 117.1, 116.9,94.8,87.5,54.4,53.6,44.9,37.2,34.2,33.3, 
ppm; MS (EI) mlz (%) 284 (17), 283 (55),282 (29), 265 (15), 229 (16), 228 (13), 227 
(10), 149 (23), 97 (11), 84 (11), 83 (15), 82 (11), 71 (17), 70 (15), 69 (18), 57 (30), 56 
(13),55 (23),46 (20), 45 (100),44 (45) ; HRMS (EI) calcd for C17H17N03: 283.1208, 
found 283.1214. 
Noroxycodone (35). 
The title compound 35 was isolated following the protocol for biotransformations 
using Cunninghamella echinulata, ATCC 9244 in 15 % yield as colorless oil in 80 % 
purity. Data for 35 matches closely to those published in the literature.96 Rf 0.21 
(DCM : MeOH : N~OH, 98:2:1); [a]D20 = -102.668° (c = 0.875, MeOH); literature 
value is [a]D25 = +100.4° (c = 0.55, MeOH)lOl(enantiomer); IR (film) Vmax: 3399,3350, 
3007,2932,2838, 1725, 1636, 1608, 1505, 1440, 1277, 1051 cm-I; IH NMR (CDCb, 
600 MHz) D: 6.73 (d, J = 8.2 Hz, IH), 6.66 (d, J = 8.2 Hz, IH), 4.68 (s, IH), 3.92 (s, 
3H), 2.95 - 3.28 (m, 3H), 2.68 -2.86 (m, 2H), 2.22 - 2.50 (m, 3H), 1.85 - 1.97 (m, IH), 
1.47 - 1.74 (m, 2H) ppm; MS (EI) mlz (%) 301 (5),88 (11), 86 (65), 84 (100), 83 (12), 
49 (18),47 (23); HRMS (EI) calcd for C17HI9N04: 301.1314, found 301.1316. 
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MeOlA MeOlA 
I...:::: I...:::: 
o -: 0 -: <-:.~NMe ·\~NMe 
HO"V HOAJ 
Dihydrocodeine (38) and iso-dihydrocodeine (41). 
A mixture of compound 38 and 41 (ratio 5: 4) was isolated following the protocol for 
biotransformations using Curvularia lunata, ATCC 12017, in 40% combined yield as 
colorless oiL Careful purification by flash column chromatography (CHCbIMeOH) 
allowed for the preparation of analytical pure samples. Data for dihydrocodeine (38) 
are identical to those published in the literature.97 Rf 0.55 (DCM : MeOH : NH40H, 
1 . 98:2:1); H NMR (CDCb, 600 MHz) B: 6.74 (d, J = 8.1 Hz, IH), 6.65 (d, J = 8.2 Hz, 
IH), 4.62 (d, J = 5.7 Hz, IH), 4.03 - 4.08 (m, IH), 3.89 (s, 3H), 3.08 - 3.12 (m, IH), 
3.02 (d, J = 18.3 Hz IH), 2.53 (dd, J = 12.0,4.6 Hz IH), 2.36- 2.44 (m, 4H), 2.20 -
2.29 (m, 2H), 1.90 (td, J = 12.3, 5.0 Hz, IH), 1.69 - 1.75 (m, IH), 1.55 - 1.62 (m, IH) 
1.41- 1.53 (m, 2H), 1.10 - 1.19 (m, IH) ppm; 13C NMR (CDCb, 150 MHz) B: 146.2, 
141.6, 130.4, 127.0, 119.2, 113.1, 90.5, 67.2, 59.7, 56.4, 46.8, 43.0, 42.2, 40.7, 37.5, 
27.2, 20.0, 19.2 ppm; MS (EI) mlz (%) 302 (20), 301 (100), 300 (23), 299 (32), 244 
(14),243 (11),242 (19), 185 (12), 164 (16), 115 (10), 70 (19), 59 (24), 44 (23); HRMS 
(EI) calcd for C18H23N03:301.1678, found 301.1678. 
Data for iso-dihydrocodeine (41) are identical to those published in the literature97. Rf 
0.51 (DCM: MeOH: N~OH, 98:2:1); IH NMR (CDCb, 600 MHz) B: 6.73 (d, J = 8.2 
Hz, IH), 6.65 (d, J = 8.2 Hz, IH), 4.37 (d, J = 6.5 Hz, IH), 3.89 (s, 3H), 3.43 - 3.50 
(m, IH), 3.09 (m, IH), 3.03 (d, J = 18.3 Hz, IH), 2.53 (dd, J = 11.9,4.5 Hz, IH), 2.42 
(s, 3H), 2.36 (dd, J = 18.3,5.3 Hz, IH), 2.12 - 1.23 (m, 2H), 1.80 - 1.90 (m, 2H) 1.69-
73 
1.74 (m, IH), 1.56 - 1.63 (m, IH), 1.38 (q, J = 12.9 Hz, IH), 1.00 (q, J = 12.9 Hz, IH) 
ppm; 13C NMR (CDCh, 150 MHz) 8: 144.1, 143.5, 130.5, 126.7, 119.0, 113.3, 97.2, 
73.3, 59.4, 56.5, 47.0, 43.2, 43.0, 42.9, 35.6, 30.0, 23.7, 20.1 ppm; MS (EI) mlz (%) 
302 (20), 301 (100),300 (20), 299 (16), 286 (11), 244 (26), 242 (12), 185 (12), 86 (50), 
84 (73), 70 (21), 59 (31), 57 (32), 56 (21), 55 (11),49 (12), 47 (14),44 (23); HRMS 
(EI) calcd for CIsH23N03:301.1678, found 301.1672. 
Meo~ 
,M Q~~ -'. NH 
OH 
HO'" h-
14-hydroxycodeine (40). 
The title compound 40 was isolated following the protocol for biotransformations 
using Trametes sanguinea (ATCC 14622) and Trametes cinabarina (ATCC 14623) 
in 35-50% yield as colorless solid. mp 109 -111°C (MeOH/diethyl ether); Rf 0.25 
(DCM : MeOH : N~OH, 98:2:1); [a]D20 = -127.89° (c = 0.3, CHCh); [a]D = -129.5° 
(c = 1.75, CHCh)l04 ; IH NMR (CDCh, 600 MHz) 8: 6.65 (d, J = 8.2 Hz, IH), 6.57 (d, 
J = 8.2 Hz, IH), 5.91 (d, J = 9.8 Hz, IH), 5.49 (dd, J = 9.9, 2.9 Hz, IH), 4.87 (d, J = 
6.5 Hz, IH), 4.60 - 4.65 (m, IH), 3.83 (s, 3H), 3.18 (d, J = 18.5 Hz, IH), 3.03 (d, J = 
6.4 Hz, IH), 2.98 (d, J = 10.2 Hz, IH), 2.45 - 2.57 (m, 2H), 2.41 (s, 3H), 2.35 - 2.39 
(m, 2H), 1.72 -1.79 (m, IH) ppm; 13C NMR (CDCh, 150 MHz) 8: 145.5,142.5,138.1, 
132.3, 128.8, 125.8, 119.3, 113.1, 90.0, 68.7, 65.2, 64.0, 56.3, 46.7, 45.2, 42.8, 31.7, 
22.2 ppm; MS (EI) mlz (%) 316 (20), 315 (100), 313 (12),230 (19), 229 (31), 188 (16), 
175 (11), 143 (31),141 (12),140 (21),131 (14), 150 (12), 70 (56), 58 (17), 55 (11), 44 
(58); HRMS (EI) calcd for C1sH2IN04: 315.1471, found 315.1470. 
74 
14-hydroxydihydrocodeine (39). 
The title compound 39 was isolated following the protocol for biotransformations 
using Trametes sanguinea (ATCC 14622) in 10- 15% yield as colorless oiL Data eH 
NMR and 13C NMR) for compound 39 were found to be identical to the major isomer 
obtained from the reduction of oxycodone with sodium borohydride in methanoL Rf 
0.35 (DCM : MeOH : NH40H, 98:2:1); [a]o20 = -93.120 (c = 0.65, CHCI3); literature 
values are [a]o = -1690 (c = 0.6, CHCh)104, [a]o = -1380 (c = 1.8 in 10% acetic acid)104; 
IH NMR (CDCh, 600 MHz) 0: 6.78 (d, J = 8.2 Hz, IH), 6.62 (d, J = 8.2 Hz, IH), 4.78 
(d, J = 6.5 Hz, IH), 4.12 - 4.29 (m, IH), 3.88 (s, 3H), 3.14 (d, J = 18.5 Hz, IH), 2.80 
(d, J = 5.5 Hz, IH), 2.60 (dd, J = 18.5, 5.6 Hz, IH), 2.40 - 2.51 (m, IH), 2.38 (s, 3H), 
2.19 - 2.31 (m, 2H), 1.74 - 1.89 (m, IH), 1.38 - 1.70 (m, 3H), 1.09 - 1.28 (m, IH) 
ppm; 13C NMR (CDCh, 150 MHz) 0: 146.5, 141.7, 131.4, 126.1, 118.9, 113.8, 90.8, 
70.0,66.7,64.7,56.5,46.3,45.0,43.1,33.2,28.2,23.7, 22.1 ppm. 
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8. Appendix 1 
Table 1: Attempts to develop an enzyme assay using Method 1. Depending on the 
assay being conducted, they contained 0.5 mg crude protein extract, Thebaine, 
NADPH or a-Ketoglutarate. Enzyme assays lasted for I h at 37°C. Enzyme assays 
conducted with denatured protein (B) were performed by boiling extracts for 10 min 
before assay. At the end of the enzyme assay, samples were extracted for alkaloids as 
described in Materials and Methods. 
Sample Protein NADPH Thebaine a-Ketoglutarate 
I + + + -
2 + - + -
3 +B + + -
4 + - + 2mM 
5 +B - + 2mM 
'+' indicates the presence of the substance and '-'indicates the absence of the 
substance in the enzyme assays. 
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Table 2: Attempts to develop an enzyme assay using Method 2. Depending on the 
assay being conducted, they contained 0.76 mg crude protein extract, Thebaine, 
NADPH, a-Ketoglutarate, Ferrous ions, Ascorbic acid, Flavin adenine mononucleotite 
(FMN) or Flavin adenine dinucleotide (FAD). Enzyme assays lasted for 1 hat 37°C. 
Enzyme assays conducted with denatured protein were performed by boiling extracts 
for 10 min before assay. At the end of the enzyme assay, samples were extracted for 
alkaloids as described in Materials and Methods. 
Enzyme Assay 1 2 3 4 5 6 7 8 
Protein (500 /J.L) + +B + +B + +B + +B 
Thebaine (50 /J.g) + + + + + + + + 
NADPH(1 mM) + + - - - - + + 
NADH(1 mM) - - + + - - - -
a-keto glutarate (2 mM) - - - - + + - -
Ferrous (1 mM) - - - - + + - -
Ascorbic acid (250 mM) - - - - + + - -
FMN(1 mM) 
- - - - - - + + 
FAD (1 mM) - - - - - - + + 
'+' indicates the presence of the substance and '-'indicates the absence of the 
substance in the enzyme assays. 
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Table 3: Enzyme assays using higher (approximately double compared to table 2 
assays) concentration of thebaine. Two controls were used in which one did not have 
any co-factors and the other did not have the substrate thebaine in order to avoid false 
positive reactions. Stock solution was prepared by making a saturated solution (1.5 mg 
thebaine in 40 ilL DMSO) of thebaine in DMSO. Concentration of total proteins was 
l.4mg/mL. 
Sample 1 2 3 4 5 6 7 8 9 10 11 12 
Protein (500 ilL) + + + + + + + + + + + + 
Thebaine (5 ilL from stock) + + + + + + + + + + + -
NADPH(1 mM) + + - - - - + + - - - -
NADH(1 mM) - - + + - - - - - - - -
a-keto glutarate (2 mM) - - - - + + - - - - - -
Ferrous (1 mM) - - - - + + - - - - - -
Ascorbic acid (250 mM) - - - - + + - - - - - -
FMN(1 mM) - - - - - - + + - - - -
FAD (1 mM) - - - - - - + + - - - -
AdoMet (1 mM) - - - - - - - - + + - -
AdoCys (1 mM) - - - - - - - - + + - -
'+' indicates the presence of the substance and '-'indicates the absence of the 
substance in the enzyme assays. 
In the above experiment the cells were first ground using mortar and pestle and the 
homogenate was subjected to sonication. The sonication buffer contained 1mM DTT 
94 
(dithiothreitol), 14 mM ~-mercaptoethanol and 50mM Tris HCI buffer at pH-7.5. After 
sonication, the crude extract was filtered through a layer of mira cloth and was 
centrifuged at 500g for 10 minutes at 4°C. The supernatant was desalted through 
PDlO column and the filtrate was used for enzyme assays. The incubation of enzyme 
was done at 37°C with the substrate and co-factors for one hour. 
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Table 4: Enzyme assays using Gibson's procedure. Concentration of total proteins was 
3.75 mglmL before desalting and 2.6 mglmL after desalting through PD 10 column. 
Sample Protein Thebaine NADPH NADH Ferrous Semicarbazide- Glycine 
ImL 100 ~g ImM ImM 5mM HCI lOmM 
30mM 
1) +(not + + + + + -
desalted) 
2) + + + + + + -
(desalted) 
3) + + + + + - + 
(desalted) 
4) + + - - - - -
(desalted) 
5) + - - - - - -
(desalted) 
'+' indicates the presence of the substance and '-'indicates the absence of the 
substance in the enzyme assays. 
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Table 5: SO mM Tris buffer at pH-7.S was used to extract fungal proteins. 
Sample Protein Thebaine NADPH NADH Ferrous Semicarbazide-HCI 
2mL 200 ~g ImM ImM SmM 30mM 
1) + + + + + + 
2) + + - - - -
3) + - - - - -
'+' indicates the presence of the substance and '-'indicates the absence of the 
substance in the enzyme assays. 
The above set of experiments (table 6) were repeated separately by using 66 mM 
phosphate buffer with pH- 7.0 and 66 mM phosphate buffer with pH- 7.5 as extraction 
buffers for protein extraction from fungal cells. Concentration of total proteins in Tris 
buffer was 1 mg! mL, in phosphate buffer pH- 7.0 was I.S mg!mL and in phosphate 
buffer at pH- 7.S was 1.2 mg!mL. But none of the experiments provided a positive 
result. 
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